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1. INTRODUCTION 
Viruses are subcellular infectious agents that are obligate intracellular parasites. 
Different viruses infect different hosts and, to a variable extent, take over host 
cells to replicate and produce mature progeny, namely, virus particles called 
virions. For these reasons, most viral infections are harmful and may eventually 
result in the death of the host cell. However, such instances of cell death are not 
always due to the specific actions of a virus: in multicellular organisms, for 
example, the death of virus-infected cells is commonly employed as a defense 
against viral infection. Hence, many viruses potently suppress cell death, espe-
cially during the early stages of viral infection. This is one of the reasons why a 
complex network of regulated interactions lies at the interface of viral infection 
and host antiviral response.  
Alphaviruses are a group of globally distributed arthropod-borne positive-
strand RNA viruses. This group includes several important human pathogens, 
including the re-emerging Chikungunya virus (CHIKV). Recent outbreaks of 
CHIKV infection have been responsible for millions of cases of acute illness 
and frequently result in long-term complications. There is no specific antiviral 
drug treatment or licensed vaccine available for the clinical management of 
CHIKV infection. One of the obstacles in the identification of new therapeutic 
agents and strategies against CHIKV has been the lack of suitable technical 
tools for CHIKV research. Thus, the study of the molecular biology of CHIKV 
is an important field of ongoing investigation. At the present time, numerous 
questions related to the molecular, cellular and organism levels of CHIKV 
infection remain unanswered. 
CHIKV nonstructural protein 2 (nsP2) is a multifunctional protein, which, in 
addition to its functions as part of the virus replicase complex, counteracts 
interferon (IFN) expression and signaling. Furthermore, nsP2 induces 
cytopathic effects and the general shutdown of transcription and translation in 
vertebrate cells. Such shutdown is essential for limiting the production of antivi-
ral proteins, mainly type I IFNs, which play a role in early innate immune 
response and are a first-line defense mechanism against viral infection. This 
shutdown also benefits the virus by reducing the capacity of an infected cell to 
signal surrounding cells via type I IFNs and other cytokines, thus expediting 
viral propagation. Depending on the balance of virus-induced cytotoxicity and 
cellular defense mechanisms, infection can end in either death of the host, per-
sistent infection, or elimination of the virus. In the case of CHIKV, the exact 
outcome of infection is highly dependent on the activities of nsP2. Some muta-
tions in nsP2 are involved in establishing a persistent infection and have been 
shown to prolong the survival of infected vertebrate cells. Such mutations can 
be used to adapt the alphavirus replicons for noncytotoxic growth in vertebrate 
cells or, possibly, to generate attenuated viruses that can be used as vaccines. 
The central aim of the studies that form the basis of the current thesis was to 
develop and apply novel tools to study the molecular biology of CHIKV and to 
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gain insight into different aspects of virus-host interactions. This resulted in the 
creation of a large set of useful tools, the properties of which are highlighted 
below. The use of these tools led to several expected and unexpected findings. 
Interestingly and importantly, studies dedicated to seemingly different aspects 
of CHIKV molecular biology came together to produce a cohesive understand 
of the virus, indicating that they were not actually focused on different char-
acteristics of viral infection but rather on different facets of the same process. 
Realization of this fact allowed better understanding of CHIKV replication and 
provided novel insights into the interactions that exist between alphaviruses and 
innate immune response pathways. 
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2. REVIEW OF LITERATURE 
2.1 Alphaviruses 
Viruses are the most numerous propagating biological objects on Earth, out-
numbering living cells by at least an order of magnitude. They are also the only 
biological objects that may have genetic material other than double-stranded 
(ds) DNA. In fact, the largest group of viruses currently known possess single-
stranded (ss) positive-strand RNA genomes. This group is also extremely 
diverse and consists of many recognized orders, families and genera as well as 
many unclassified viruses (and, by all likelihood, even larger numbers of 
unknown viruses). Each of these viruses has many unique properties as well as 
characteristics shared with several, many or even all positive-strand RNA 
viruses. 
The Togaviridae family, a relatively small family of positive-strand RNA 
viruses, is divided into two genera: Alphavirus and Rubivirus. Their genomic 
organization is rather similar, despite that phylogenetic analyses have indicated 
that they are only distantly related (1). The genus Rubivirus contains a single 
member (rubella virus), while there are over 30 currently recognized members 
of the genus Alphavirus (2). Most alphaviruses are transmitted by arthropod 
vectors (usually mosquitoes) to a wide range of vertebrate species (most com-
monly birds or mammals). Infection of insect vectors is persistent and lifelong, 
with minimal effect on the viability of the vector; conversely, in vertebrates, 
infections are mainly acute and self-limiting, ending with the death of the host 
or clearance of the pathogen by the immune system. Thus, most alphaviruses 
are classical arboviruses (3). The few exceptions include fish-infecting 
alphaviruses, which lacks known arthropod vector, and the recently discovered 
Eilat virus, which infects only mosquitoes and cannot replicate in vertebrate 
cells (4, 5). 
Alphaviruses that infect birds and mammals can been divided into New 
World and Old World viruses, depending on their geographic distribution (6). 
New World alphaviruses, including Eastern equine encephalitis virus, Vene-
zuelan equine encephalitis virus (VEEV) and Western equine encephalitis virus 
(WEEV), are found in North and South America and typically cause encephali-
tis in humans and other mammals. Old World alphaviruses, such as 
Chikungunya virus (CHIKV), O’nyong’nyong virus (ONNV), Ross River virus 
(RRV), Semliki Forest virus (SFV) and Sindbis virus (SINV), are found in 
Europe, Africa, Asia and Australia (6, 7). Old World alphaviruses generally do 
not cause encephalitis (though it can occur, especially in experimental models); 
instead, they cause illness characterized by fever, rash, chills, headache, myal-
gia, vomiting and arthralgia. The disease is commonly acute; however, for some 
of these viruses (most notably CHIKV, see below), debilitating joint pain can 
persist for months to years after infection. Chronic disease has been linked to 
persistent viral replication in target cells and/or the establishment of a self-
sustained inflammatory mechanism that leads to tissue damage (8–10).  
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The genus Alphavirus is endemic on all six continents. Historically, the 
range of individual species of alphavirus was confined to certain regions by 
environmental barriers and/or the geographical distribution of suitable vectors. 
However, climate change, globalization and the ease of overseas travel have 
increased the spread of alphaviruses to other regions habituated by competent 
mosquito vectors. Typically, the human populations inhabiting such regions 
lack pre-existing immunity. Thus far, only one alphavirus, CHIKV, has man-
aged to achieve a large-scale spread in this manner (11, 12); however, in the 
future, other alphaviruses may also spread. CHIKV has historically caused 
small outbreaks in confined regions within Africa and Asia (13). However, it is 
possible that some outbreaks that have not been recognized as Chikungunya 
fever have occurred outside of this region. The 2004–2007 epidemic in the 
Indian Ocean region and India demonstrated the potential of CHIKV to rapidly 
spread and establish itself in previously unaffected areas (11, 14). This was 
further emphasized in late 2013, when a locally transmitted CHIKV infection 
was detected on St. Martin Island in the Caribbean, and the virus subsequently 
became established in Central and South America, Mexico and the mainland 
United States (12). To date, CHIKV has been identified in over 60 countries in 




Figure 1. Global distribution of CHIKV as of October 2015. Countries and territories 
with local transmission are shown in dark green  
(http://www.cdc.gov/chikungunya/geo/index.html, permission obtained from the Centers 




Many well-studied alphaviruses have several different strains and genotypes 
that are found in different areas and/or associated with different diseases/ 
symptoms. It should be noted that the classification of alphaviruses into strains, 
genotypes and lineages is not firmly established, and different terms are often 
used to designate the same viruses. Three CHIKV genotypes have been 
identified since its discovery in Tanzania in 1952: the West African (WA) 
genotype, East/Central/Southern African (ECSA) genotype and Asian genotype 
(15). Viruses belonging to the ECSA and WA genotypes have approximately 
5% differences in the amino acid (aa) sequences of their encoded proteins. 
These differences are not evenly distributed and are most common in the C-ter-
minal region of nsP3 (see below). The most variable part of the CHIKV genome 
(also other alphaviruses), however, is the 3’ untranslated (UTR) region, which 
displays considerable variations in length, sequence and other properties (16, 
17). These differences create the possibility that at least some functions of 
alphavirus-encoded proteins or of the cis elements of alphavirus genomes may 
differ between different CHIKV genotypes. 
The Indian Ocean lineage (IOL) of CHIKV is a variant of the ESCA geno-
type that arose in 2004 (18, 19). Several IOL strains have adapted to a new vec-
tor, Aedes albopictus, without significantly compromising viral fitness in the 
initial vector, Aedes aegypti, thereby increasing the epidemic potential of the 
virus. Genomic sequencing of CHIKV isolates with increased infectivity for 
Aedes albopictus revealed one single aa change, in the virus envelope gly-
coprotein E1 (Ala226 to Val), that is responsible for the above phenotype, 
demonstrating how easily alphaviruses can switch to new vectors or increase the 
number of vector species they can infect (20).  
 
2.1.1 Alphavirus virion 
Alphaviruses have enveloped virions of approximately 70 nm in diameter. A 
single copy of a positive-strand RNA genome is assembled with 240 copies of 
capsid protein into a T=4 icosahedral nucleocapsid with a diameter of 40 nm 
(21). The nucleocapsid is surrounded by a host-derived lipid bilayer in which 
two transmembrane envelope glycoproteins, E1 and E2, are embedded. These 
two proteins are organized as 80 trimers of heterodimers (thus, the structure is 
3×(E1+E2)), which are referred to as spikes (22, 23) (Fig. 2). The glycoprotein 
spikes and the nucleocapsid core are linked through interactions that occur 
between the capsid proteins and the cytoplasmic tails of E2; this interaction 
ensures 1:1 ratio of capsid protein and E1+E2 dimers in virions (24–27). This, 
together with size and structure of glycoproteins, ensures that alphavirus virions 
have very regular structure and that the membrane layer is fully covered by an 
outer glycoprotein layer. The regular structure of the alphavirus virion and the 
stability of its major glycoproteins have facilitated analyses of the molecular 
details of virion structure. For CHIKV, the 3D structure of E1-E2 dimers (both 
in mature form and as precursors) has been resolved and, in combination with 
high quality cryo-electron microscopy data, it has resulted in a high-resolution 




Figure 2. Schematic representation of an alphavirus virion. The alphavirus virion 
consists of a nucleocapsid surrounded by a lipid bilayer. The nucleocapsid is formed by 
a positive-strand RNA genome (grey) and 240 copies of capsid protein (lightest blue). 
The lipid bilayer (orange) is embedded with 240 heterodimers of the viral glycoproteins 
E1 and E2 (blue and light blue), which are arranged into 80 spike structures. 
 
The E2 protein is responsible for receptor binding (29, 30). It is also the major 
antigen of the alphavirus virion and a target for broadly neutralizing antibodies 
that block both the entry and the egress of alphavirus virions (31). The E1 pro-
tein includes a fusion peptide that becomes exposed under low pH conditions, 
such as in endosomes. This initiates the fusion of the viral envelope and the 
endosomal membrane and ensures the release of the nucleocapsid into the host 
cell cytoplasm (32, 33). Moreover, alphavirus virions contain two small mem-
brane-association proteins known as 6K and transframe (TF) (34, 35). The 
virions of some alphaviruses (such as SFV) also contain a third small glyco-
protein, known as E3; however, this protein is not incorporated into CHIKV, 
SINV or WEEV virions (36). The 6K, TF and E3 proteins are important for 
regulating spike assembly and are necessary for efficient budding of the virus 
(37–39). E3 also has a role in protecting the E1 protein against the low pH con-
ditions found in the secretory pathway and thus prevents premature exposure of 
the fusion peptide (40). The precise roles of the 6K and TF proteins are not 
known; however, both proteins affect the ability of virus to replicate (most 
likely influencing the release of virions from infected cells) and have impact on 
in vivo pathogenesis (41, 39, 38). 
 
2.1.2 Genome organization 
The alphavirus genome is a positive-stranded RNA molecule of approximately 
12 kilobases (kb) in length. As in all positive-strand RNA viruses, the naked 
RNA genome of alphaviruses is sufficient to initiate the complete replication 
cycle (42).  
The coding sequence of the genome consists of two large open reading 
frames (ORFs), which encode 10 proteins in total (Fig. 3). The first ORF, 
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covering approximately two-thirds of the genome, is translated directly from the 
genomic RNA and encodes the nonstructural (ns) polyprotein or polyproteins, 
depending on the presence or absence of a stop codon at the end of the nsP3 
coding region. The ns polyprotein and nsPs are virus-specific components of 
the alphavirus replicase complex. The second ORF, corresponding roughly to 
one-third of the genome, encodes the structural proteins that function in the 
assembly of new virus particles and may also have other functions in the virus 
replication cycle. This ORF is translated from a subgenomic (SG) mRNA using 
an internal SG promoter located on the negative strand of a dsRNA replicative 
intermediate (42, 43). Both the genomic and SG RNA have a 5´ terminal cap 
structure and poly(A) tail on the 3´ end similar to eukaryotic mRNA (7). These 
elements are required for the stability and translation of the viral genome, as 
well as for its efficient replication and transcription. Interestingly, it was 
recently described that noncapped versions of these RNAs are also produced at 




Figure 3. Alphavirus genome organization (above) and order of nonstructural 
polyprotein processing at early stages of infection (below). The alphavirus genome 
contains two ORFs that encode both ns and structural proteins. The precursor of the ns 
proteins (nsP1, nsP2, nsP3, and nsP4) is translated directly from the genomic RNA 
(green region). The precursors of the structural proteins (C, E3, E2, 6K, TF and E1) are 
translated from the SG RNA (blue region). The TF protein (violet) is produced by a 
ribosomal frame-shift that occurs in the region encoding the 6K protein. At early stages 
of infection, the protease activity of nsP2 cleaves the P1234 polyprotein into P123 and 
nsP4 (early replicase), which are subsequently processed into the short-lived 
nsP1+P23+nsP4 complex and finally into the late replicase, which consists of mature 
nsPs. This is the only expression and processing pathway leading to formation of func-




In addition to its coding sequences, the alphavirus genome contains a short 5’ 
UTR, a 3’ UTR of variable length and a short intergenic region between the ns- 
and structural ORFs (7). All these regions contain important cis-acting ele-
ments. The most important cis-acting elements are conserved between different 
alphaviruses and are therefore called conserved sequence elements (CSE). In 
total, there are four CSEs in the alphavirus genome, and all are necessary for the 
replication and transcription of the virus RNA (2, 7): 
– CSE1 approximately corresponds to the 44 first nucleotides (nt) located at 
the 5’ end of the genome. This region forms a stem-loop structure that is 
important for the initiation of negative-strand RNA synthesis (45). In the 
context of negative-strand RNA, CSE1 functions as a promoter for positive-
strand RNA synthesis (46). Interestingly, the secondary structure of this 
region was identified as a determinant of alphavirus pathogenicity. The 
structure was shown to mask the viral cap0 structure, which differs from the 
cellular cap1 structure and should therefore be recognized by the host IFN-
induced protein with tetratricopeptide repeats (IFIT1) (47, 48). Thus, the 
presence of the specific RNA structure prevents the detection of viral RNA 
by the host and the subsequent activation of the innate immune system, 
resulting in enhanced translation and replication of the alphaviral genome in 
vertebrate cells. 
– CSE2 (51 nt in length) is located near the 5′ end of the genome within the 
sequence that encodes nsP1; its secondary structure is represented by two 
stem-loop structures (46). This element enhances both negative- and posi-
tive-strand RNA synthesis (45). However, it has been shown that CSE2 is 
required only in insect cells and not in vertebrate cells, suggesting its pos-
sible recognition by host cell type specific factors (49).  
– CSE3 overlaps with the sequence that encodes the C-terminus of nsP4 and, 
for some alphaviruses, extends to the intergenic region (43). CSE3, which is 
24 nt in length, is also referred to as the minimal SG promoter because it is 
essential for the synthesis of SG mRNA. The SG promoter (in its full-length 
form) is exceptionally efficient. It is frequently used in alphavirus-based 
expression systems, where a duplicated SG promoter drives the expression 
of a gene of interest concurrent with virus replication (50–52).  
– CSE4 is a 19-nt element located immediately before the poly(A) tail. It acts 
as a part of the promoter required for the synthesis of positive-strand RNA, 
probably via interaction with the 5′ and 3′ ends of the full-length genomic 
RNA. It also contains the start site for negative-stand RNA synthesis (45, 
53). To be functional, CSE4 must be followed by at least 11 adenosine resi-
dues (54). 
 
In addition to the CSEs needed for RNA replication or transcription, the 
alphavirus genome contains the following structured RNA elements that are 
also important for alphavirus infection: 
– The packaging signal for the alphavirus genome is located in ns region of the 
genome. The position of this signal varies between different alphavirus 
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species (55, 56). For most alphaviruses, it is located in the region encoding 
nsP1; however, for members of the SFV group (including CHIKV), the 
packaging signal is located in the region encoding the protease domain of 
nsP2 (57). 
– Many alphaviruses, including VEEV and SINV, contain a specific signal 
(stem-loop RNA structure) that enhances read-through of the in-frame 
termination codon, which is present at the end of the sequence encoding 
nsP3 (58). 
– In some alphaviruses (SFV, SINV), the 5’ end of the sequence encoding the 
capsid protein contains a translational enhancer, which is needed for effi-
cient translation of the viral structural proteins in an infected cell. Recombi-
nant viral vectors that lack this enhancer produce approximately 10–fold less 
protein from their SG RNA than those that contain the enhancer (59, 60). 
However, the function of this region as a capsid enhancer is not conserved 
among the alphaviruses; it is apparently absent from the genomes of several 
members of the genus, including VEEV and CHIKV.  
– Another interesting feature of the SG RNA is that the reading frame for the 
structural proteins contains a −1 ribosomal frameshift signal located in the 
sequence encoding the 6K protein. This frameshift event leads to the expres-
sion of the structural TF protein (35). 
– Many cis-acting sequences are located in the 3’ UTR. These elements are 
often present as repeated sequence elements, and their copy numbers (and 
thus the length of the 3’ UTR) show considerable variation. These sequences 
are needed for host-specific adaptation and are also important for stability of 
alphavirus RNA (16, 17, 61, 62).  
 
 
2.2 Alphavirus infection cycle 
The currently available information about the alphavirus infection cycle is 
fragmented: some stages of the infection process have been studied using one 
virus, while other stages have been studied using another virus. These pieces of 
information have been combined to obtain a general picture. The problem with 
this approach is that several studies have shown that not all key processes are 
executed in the same manner by all alphaviruses. Furthermore, two of the most 
well studied alphaviruses, SFV and SINV, are not really closely related; hence, 
the data obtained from studying these viruses are sometimes contradictory. 
Other alphaviruses that have also been studied in more detail include VEEV 
(a New World alphavirus) and CHIKV (phylogenetically relatively close to 
SFV). The resulting picture presents a puzzle where some parts are missing and 
some fragments are probably incorrectly placed. However, as replication is the 
most conserved process in viral infection, it is reasonable to assume that the 
picture that has been generated reflects an “average” situation relatively well 
and can be applied (with some modifications) to each individual alphavirus.  
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In vivo alphavirus infection starts when an infected mosquito feeds on a 
vertebrate host. The initial stages of in vivo infection are relatively poorly 
understood. Infection begins in the tissues surrounding the bite or in regional 
lymph nodes and then spreads to other organs. The landmark of alphavirus 
infection is the presence of a very high amount of virus in blood (viremia) that 
is required to infect mosquitoes and ensures viral transmission. However, as the 
infection is usually self-limited, an infected vertebrate is only capable of 
infecting mosquitos for a relatively brief period of time, namely, after viremia is 
established but before the immune response limits the amount of circulating 
virus (63). 
During mosquito feeding, alphavirus virions are thought to be released 
within the dermis and into the subcutaneous capillaries of the skin. The virus 
delivered by mosquito (possibly around 100 plaque forming units/bite) is more 
infectious than the same amount of virus delivered by injection. This indicates 
that mosquito saliva has a role in the early stages of in vivo infection, although 
the molecular basis of this phenomenon has only resently started to emerge 
(64). Depending on the host and virus, alphaviruses reach the blood within 2–4 
days and then disseminate to other parts of the body. The sites of subsequent 
virus replication vary with the virus and the host. The target organs of CHIKV 
include joints, muscles, skin, and, less frequently, liver, kidneys, eyes and the 
central nervous system. Infection of these organs is frequently associated with a 
marked infiltration of mononuclear cells such as monocytes/macrophages (65–
67). During the 7- to 12-day-long acute viremic period, CHIKV load can reach 
109–1012 viral particles per milliliter of blood. Viral RNA can persist in synovial 
macrophages for many weeks (and sometimes month or years) after clearance 
of the virus from blood (68). The significance of this phenomenon for the virus 
transmission cycle is not known. It should also be noted that the basic steps of 
alphavirus infection in mosquitoes are quite different from those in vertebrate 
hosts; in mosquitoes, infection beings in the midgut, and the virus disseminates 
to different organs, including the salivary glands. In case of both vertebrate and 
mosquito hosts, the replication cycle of alphavirus, especially the molecular 
details, are better known for in vitro system. Hence, most of the data reviewed 
below originated from different (mostly vertebrate) in vitro models. 
 
 
2.2.1 Binding and entry 
At the beginning of infection, alphavirus virions bind to receptors on the surface 
of host cells (Fig. 4). Generally these viruses are able to infect a large variety of 
cell types as well as cells from very different species, such as vertebrate hosts 
and arthropod vectors. The wide host range of alphaviruses may in part result 
from the ability of these viruses to bind to different receptors. Many proteins 
and polysaccharides have been implicated as being part of the receptor com-
plexes used by alphaviruses. However, understanding the full details of virus-
receptor interaction is challenging, as a single alphavirus can use different types 
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of receptors and, conversely, some receptors are shared between different 
alphaviruses. As a consequence, our knowledge about this step of alphavirus 
infection is fragmented. The high-affinity laminin receptor has been identified 
as a receptor for SINV in mammalian cells and for VEEV in mosquito cells (69, 
70). In addition, heparan sulfate has been also demonstrated to act as a binding 
receptor for SINV (29, 71). The natural resistance-associated macrophage pro-
tein (NRAMP; a divalent metal ion transporter) was shown to mediate SINV, 
but not RRV, entry into both mammalian and insect cells (72). Recently, many 
new receptor candidates for CHIKV have been found. For example, prohibitin, 
phosphatidylserine receptor TIM-1 and glycosaminoglycans have all been sug-
gested as CHIKV receptors in mammalian cells (73–75), and ATP synthase 
β subunit serves as a receptor in mosquito cells (76).  
Alphaviruses are generally internalized via clathrin-mediated endocytosis. 
Curiously, a mechanism involving direct fusion of the viral membrane with the 
plasma membrane and subsequent entry of the viral genome into cells has been 
described for SINV (77, 78). The majority of classical and novel studies, how-
ever, support viral entry by endocytosis. According to these studies, as endo-
cytosis proceeds, endosomal vesicles containing virions mature, and the pH in 
these vesicles becomes acidic. This change in pH subsequently induces confor-
mational changes within the virion envelope. Specifically, the low pH of 
endocytic vesicles destabilizes E1-E2 heterodimers and leads to the exposure of 
the fusion peptide of E1, which was previously shielded by E2 (33). Subse-
quently, the fusion peptide inserts into the endosomal membrane, where it leads 
to the trimerization of E1 proteins (79, 80). This triggers fusion between the 
viral envelope and the endosomal membrane and results in the release of the 
nucleocapsid into the host cell cytoplasm. Finally, the disassembly of the 
nucleocapsid is facilitated by ribosomes, which actively remove the capsid pro-
teins, thus releasing the genomic RNA and enabling the initiation of ns 





Figure 4. Alphavirus infection cycle. Alphavirus infection starts when a virion binds 
to a cellular receptor and then enters into the cell by clathrin-dependent endocytosis. 
The fusion of endosomal and virion membranes is triggered by low pH and results in 
the release of nucleocapsids, and subsequently viral genomic RNA, into the cytoplasm. 
The genomic RNA is immediately translated to yield the P1234 polyprotein (green), 
which is converted into the viral replicase through well-ordered proteolytic processing. 
The early replicase synthesizes a complementary (negative) RNA strand, leading to the 
formation of a dsRNA replication intermediate, which is subsequently used by the late 
replicase to create new genomic and subgenomic RNA molecules. The subgenomic 
RNA drives the expression of the structural polyprotein, which is co- and post-trans-
lationally processed. The C protein self-releases and associates with newly synthesized 
genomic RNA to form the nucleocapsid. The processing and maturation of the viral 
glycoproteins occur in the ER and Golgi. Mature glycoproteins are then transported to 
the plasma membrane. The nucleocapsid associates with glycoproteins and this binding 
event triggers the budding and the release of the virion. 
 
 
2.2.2 Replicase expression and viral RNA replication 
Almost all of what is known about alphavirus replicase expression and RNA 
replication has originated from studies of SFV and SINV. It is commonly 
assumed (though almost never directly proven) that these findings apply to 
other alphaviruses as well. 
Once inside a cell, the positive-strand viral RNA genome directly serves as 
mRNA for ns polyprotein synthesis (83). For most alphaviruses (e.g. SINV and 
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VEEV), the prominent ns polyprotein is P123, as there is an opal termination 
codon in the end of the region encoding nsP3. A translational read-through, 
occurring with 10–20% efficiency, results in the synthesis of the P1234 
polyprotein, which also contains the RNA polymerase (nsP4) region (84). In 
some strains of SFV, ONNV and CHIKV, the opal terminator is absent, and the 
only translational product of the virus genome is the P1234 polyprotein (85, 86).  
The alphavirus RNA genome serves as a template both for the expression of 
replicase proteins and for the synthesis of negative-strand RNA. These func-
tions are, however, mutually exclusive (they cannot occur on the same RNA at 
the same time). Hence, a mechanism(s) that enables a switch between ns 
polyprotein translation and RNA replication must exist. It has been hypothe-
sized that this switch may be mediated by the actions of host cell proteins, such 
as G3BPs (87). Alternatively (or additionally), the RNA may become inacces-
sible to ribosomes through the formation of membrane-bound replication com-
plex (RC) structures (see 2.2.3 for details). Indeed, it has been shown that 
alphavirus ns polyproteins localize to the plasma membrane and bind to the 
inner surface of this membrane; these processes are crucial for SFV infection 
(88). As ns polyproteins also bind to CSEs of the genome it is obvious that the 
viral RNA also becomes localized to the same region. However, the order of 
events that follows membrane binding has not been revealed.  
The full-length P1234 polyprotein is thought not to be capable of performing 
RNA replication. Similarly, the individual alphavirus nsPs are unable to 
assemble into functional replicase complexes (89, 90). This indicates that 
alphavirus RNA synthesis requires the presence of cleavage intermediates of the 
P1234 polyprotein. The processing of P1234 is mediated by specific protease 
activity of nsP2 or the corresponding region of the ns polyprotein (90, 91). Both 
the timing and the order of cleavage events are important: only one processing 
pathway is known to lead to the assembly of a functional replicase (Fig. 3). 
Furthermore, the activities of the replicase are controlled by changes in the ns 
polyprotein. Namely, at early stages of infection (generally up to 3–4 h post-
infection, p.i.), the P1234 is first cleaved between nsP3 and nsP4 to yield P123 
and nsP4, which form an unstable early RC (92) (Fig. 3 and 4). This early 
replicase (also called the negative-strand replicase) binds to the genomic RNA 
and uses it as a template for the synthesis of one full-length negative-strand 
RNA, which forms dsRNA with its template (92–94). Next, a second cleavage 
event occurs between the nsP1 and nsP2 regions of P123, yielding nsP1, P23 
and nsP4. This is known as the intermediate replicase complex, which theo-
retically is able to produce both positive- and negative-strand RNAs (92, 95, 
96). In reality, however, it is unlikely that this replicase produces any of these 
RNAs due to the extremely short half-life of the P23 polyprotein (97). Thus, a 
third and final cleavage (P23 into nsP2 and nsP3) follows almost immediately 
and leads to the formation of a stable complex consisting of individual nsP1, 
nsP2, nsP3 and nsP4 proteins (Fig. 3 and 4). Under normal circumstances, this 
complex is unable to synthesize negative-strand RNA; instead, it produces both 
genomic and SG RNA, and this process continues until the cell dies (92, 94).  
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It should be noted that some of these rules are not absolute. For instance, it 
has been shown that certain mutations in nsP2 result in instability of the late 
replicase and enable consistent synthesis of the negative-strand RNA (98). Fur-
thermore, some temperature-sensitive mutants of SINV can re-activate the syn-
thesis of negative-strand RNAs, even in the absence of protein synthesis (99). 
Finally, a SINV mutant that is unable to process P123 due to mutations in the 
cleavage sites is capable of synthesizing both negative- and positive-strand 
RNAs (95). These facts indicate that the processing of P123 does not change the 
specificity of the viral replicase; rather, changes in the strand specificity of the 
virus replicase control P123 processing (97). 
The produced genomic RNA can interact with newly synthesized capsid 
proteins (translated from SG RNA), resulting in the formation of nucleocapsids 
(100). However, at early stages of infection, the concentration of capsid protein 
in cells is low, and newly synthesized viral genomes re-enter into the RNA 
replication process to produce new ns polyproteins, which subsequently form 
early and late replicase complexes. However, at later stages of infection, the 
formation of new replicase complexes and the synthesis of negative-strand 
RNAs stops (101, 102). Two mechanisms contribute to this effect. First, the 
processing pattern of the P1234 polyprotein changes. This is caused by the 
accumulation of free nsP2, which cleaves new P1234 polyprotein molecules 
(possibly before their translation is completed) at the cleavage site located 
between the nsP2 and nsP3 regions. This results in the formation of P12 and 
P34 polyproteins that cannot form new replicase complexes (90) and are pro-
cessed into individual nsPs that have also functions other than participation in 
RNA replication (see 2.3). Second, the inhibition of negative-strand RNA syn-
thesis can also result from the shutdown of viral nsP expression that occurs at 
late stages of infection (7).  
 
 
2.2.3 Sites of alphavirus RNA replication 
The replication of alphaviral RNA occurs on cellular membranes. This is cer-
tainly not a unique feature, as all positive-strand RNA viruses of eucaryotes use 
and rearrange cellular membranes to create intracellular vesicles (or mem-
branous webs) as an efficient way of isolating, protecting and concentrating 
viral components and to coordinate viral replication (103, 104). Alphavirus 
RCs, also called spherules, have the appearance of bulb-shaped membrane 
invaginations. Each spherule has an inner diameter of approximately 50 nm, and 
the interior of the invagination is always connected to the cytoplasm by a nar-
row neck-like structure (105). Spherules are formed during the early stages of 
infection, as their formation requires a specific pathway of P1234 polyprotein 
processing (90). In SFV-infected cells, spherules are located on the membranes 
of modified endosomes and lysosomes; such structures are called type I 
cytopathic vacuoles (CPV-I) and represent virus replication organelles (Fig. 5). 
However, it was recently shown that spherules are initially formed at the host 
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cell plasma membrane. Spherule formation is coupled with the synthesis of 
negative-strand RNA: in its absence no spherule formation can be observed 
(106, 107). In contrast, the synthesis of positive-strand RNAs is likely not 
required (108). Spherules contain dsRNA replication intermediates inside the 
cavities (109). Electron microscopy images have revealed that the length of the 
replication template plays a decisive role in defining the size of a spherule: 
shorter templates generate much smaller spherules than the full-length viral 
template. This is concordant with idea that each spherule contains a single 
dsRNA and also indicates that there are many determinants involved in spherule 
assembly and formation (110). Clearly, spherules also contain nsPs. However, 
the exact amounts, stoichiometries and localization patterns of the nsPs that are 
contained in spherules are not known. It has been hypothesized that nsPs are 
most likely located at the vesicle necks, which act as open channels for nucleo-
tide import and newly synthesized positive-strand RNA export (105). Existing 
data also suggest that only a relatively small amount of nsPs exists in alphavirus 
spherules (106). In addition, each spherule also contains an unknown number of 
different host proteins.  
After spherules are formed, they remain on the plasma membrane for only a 
short period of time. Later, the spherules are internalized through endocytosis 
and, in the case of SFV, are transported along microtubules to the perinuclear 
region (111). During this transport, they fuse with endosomes and lysosomes, 
which leads to the formation of large CPV-I structures. Surprisingly, interrup-
tion of this process by different inhibitors has no significant effect on viral RNA 
synthesis (106, 111). Recently, RC internalization was shown to be associated 
with the ability of the nsP3 of SFV to hyper-activate the phosphatidylinositol-3-
kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway (112). 
This pathway has been previously shown to be involved in RC internalization 
(111). It was also found that mutations in SFV nsP3 that abolished this hyper-
activation PI3K-Akt-mTOR pathway also interfered with RC-internalization – 
the RCs of the mutant viruses remained localized close to the plasma mem-
brane, and large CPV-I structures were not formed. Moreover, clear differences 
between closely related alphaviruses have been documented; for example, 
CHIKV has a phenotype similar to those of mutant forms of SFV. Thus, 
CHIKV infection fails to hyper-activate the PI3K-Akt-mTOR pathway, and 
internalization of its RCs is rather inefficient, with spherules located close to the 
plasma membrane and the absence of prominent CPV-Is (112). Domain-swap-
ping experiments have demonstrated that the differences in these phenotypes 
are determined by the C-terminal hypervariable domain (HVD) of nsP3; 
experiments with mutant viruses have revealed that the crucial determinants are 
localized at the beginning of the HVD. This finding is consistent with a previ-
ous observation that the nsP3 of SFV is crucial for the localization of nsPs into 
endo- and lysosomal compartments (89). In addition, it has been demonstrated 
that similarly located regions in the SFV and CHIKV nsP3 proteins have clearly 





Figure 5. Formation of spherules during viral genome replication. (A) P1234 
polyproteins are bound to the plasma membrane via the nsP1 region. (B) P1234 is pro-
cessed into P123 and nsP4, which bind to the viral genome and initiate negative-strand 
RNA synthesis, leading to the formation of a dsRNA replication intermediate. (C) This 
process coincides with (and possibly induces) the formation of membrane-bound 
spherules on the outer surface of the plasma membrane and is followed by the processing 
of P123. These events result in the formation of late (also called positive-strand RNA) 
replicase complexes and the synthesis of genomic and SG RNAs, which are released 
from the spherules into cell cytoplasm (D). These newly created RNA genomes can bind 
to other available ns polyproteins (or serve as templates to produce more P1234), resulting 
in an increase in the number of early (and subsequently late) replicase complexes at the 
plasma membrane. (E) Continuing endocytosis results in the formation of vesicles 





2.2.4 Synthesis of structural proteins, virion assembly and budding  
During alphavirus infection, large amounts of SG RNA are produced. This SG 
RNA serves as mRNA for the production of viral structural proteins. SG RNA 
is produced by the same RCs as viral genomes but tends to be 2- to 5-fold more 
abundant than genomic RNA. This is most likely because the SG promoter 
region in the negative-strand RNA template is more efficiently used by the 
replicase than the genomic promoter region. The structural proteins are trans-
lated in the form of a C-E3-E2-6K-E1 polyprotein (or a C-E3-E2-TF poly-
protein if there is a frameshift event during translation), which is processed by a 
combination of viral and cellular enzymes (35, 113). The capsid protein con-
tains a serine-protease domain in its C-terminal region and cleaves itself off 
from the rest of the structural polyprotein. This autocatalytic cleavage exposes a 
signal peptide in E3, which inserts the glycoprotein part of structural 
polyprotein into the endoplasmic reticulum (ER), where its translation continues 
using membrane-bound ribosomes (114, 115). Next, in the ER, the structural 
polyprotein is modified (glycosylated and palmitoylated) and then cleaved into 
the p62 (precursor of E3 and E2), 6K and E1 proteins by cellular proteases 
(116, 117). Then, p62 and E1 quickly form a heterodimer, which is transported 
from the ER to the Golgi complex. In the trans-Golgi compartment, p62 is pro-
cessed by another cellular enzyme (furin) to form E2 and E3 (117). This cleav-
age completes the formation of the mature (fusion competent) E2-E1 hetero-
dimers (118), which are transported to the plasma membrane, where they are 
incorporated onto the virion surface as trimeric spikes (40, 117). The fate of the 
E3 glycoprotein depends on the virus: it is a component of some alphavirus 
virions, such as SFV (119), but absent in others including SINV and CHIKV 
(36). The small 6K protein has also been found to be incorporated into virions. 
Although this protein is important for efficient virus budding, it is not abso-
lutely required for particle release (34, 39, 37). The TF protein is also incorpo-
rated into virions, but its functions are unclear (38). 
The assembly of alphavirus virions starts with the formation of the 
nucleocapsid. This occurs in the cytoplasm near the replication sites and is trig-
gered by the recognition of an RNA encapsidation signal by the capsid protein 
(120). As the packaging signal is always localized to the ns region of the RNA 
genome, only genomic RNA is packed (121). Interaction of the capsid protein 
with the packaging signal leads to the multimerization of the capsid protein and 
results in the formation of the icosahedral nucleocapsid, which is then trans-
ported to the plasma membrane. Finally, the budding of the virus is triggered by 





2.3 Functions of alphavirus nsPs 
Alphaviruses encode four nsPs, all of which are required for the replication of 
the viral genome and the transcription of SG RNA. In addition to their functions 
as part of the viral replicase, each nsP has other important functions in the virus 





NsP1 (~60 kilodalton (kDa)) has multiple functions during alphaviral RNA 
synthesis. NsP1 is the only membrane anchor for the RC (89), it has guanine-7-
methyltransferase (MT) and guanylyl transferase (GT) activities (124, 125), and 
it participates in the synthesis of negative-strand RNA (126). More specifically, 
it has been shown that nsP1 regulates negative-strand synthesis via interactions 
with the N-terminal region of nsP4 (127, 128). 
In infected or transfected cells, free (not bound to RCs) nsP1 is found at the 
inner surface of the plasma membrane (105, 129), suggesting that it is specifi-
cally targeted there. NsP1 is tightly bound to membranes in the context of the ns 
polyproteins, in mature RCs, and as an individual protein (89). An amphipathic 
alpha helix in the central part of the protein is responsible for this membrane 
association. Interactions with membrane phospholipids mediated by the amphi-
pathic helix are essential for the enzymatic activities of nsP1 of SFV. Thus, the 
substitution of a one single critical aa residue in this area that abolishes nsP1 
membrane binding is also lethal for SFV (88). However, it has been shown that 
an association with membranes is not universally required for the enzymatic 
activities of the nsP1 for all alphaviruses (130). As described below (see 2.3.4), 
the same applies to the functional connection between nsP1 membrane asso-
ciation and the ability of the viral replicase to perform RNA synthesis. 
Palmitoylation in the C-terminal region of the protein strengthens its membrane 
binding and renders nsP1 similar to integral membrane proteins (129). Never-
theless, palmitoylation is not needed for the enzymatic activities of nsP1. Muta-
tions preventing the palmitoylation of nsP1 have been reported to render the 
virus nonpathogenic for mice (131). However, it is not clear what exactly 
causes this defect. Namely, it was shown that mutation in the palmitoylation site 
drastically diminishes SFV infectivity, most probably because it interrupts the 
interaction between nsP1 and nsP4. This interaction could be restored by the 
emergence of secondary compensatory mutations. Thus, the palmitoylation-
negative SFV used in animal experiments most likely represented a mixture of 
different pseudo-reverted viruses (132).  
The N-terminal region of nsP1 is responsible for MT/GT activities involved 
in the capping of newly synthesized viral genomic and SG RNAs (124). This 
structure is essential for mRNA translation and prevents viral mRNA from deg-
radation by cellular 5’ exonucleases. In addition, a point mutation that specifi-
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cally destroys the GT activity of nsP1 was reported to be lethal for the virus 
(133). However, when the replicase of SFV harbors mutations in the catalytic 
site of nsP1, it is clearly capable of negative-strand RNA synthesis and can 
initiate spherule formation (108). The most likely explanation for this finding is 
that the negative-strand RNA of alphaviruses is not capped and hence its syn-
thesis is not affected by mutations inhibiting cap synthesis.  
The synthesis of alphavirus cap occurs through a unique mechanism. To 
initiate capping, the RNA triphosphatase (RTPase) activity of nsP2 removes the 
gamma-phosphate from the 5’ end of the nascent RNA (134). Subsequently, 
GTP is methylated, forms a covalent m7GMP-nsP1 intermediate and only then 
gets transferred to the mRNA to create the cap0 structure. Thus, the three last 
steps of the capping reaction are carried out by nsP1 (124, 135). In contrast, 
reactions used for the synthesis of cap structures of cellular mRNAs occur in a 
different order: GMP is first covalently bound to RNA and only then becomes 
methylated (124). 
The functions of free (non-RC-associated) nsP1 are poorly understood. It has 
been shown that this protein localizes at the plasma membrane, initiates the 
disruption of the actin cytoskeleton and induces the formation of filopodia-like 
structures on the cell surface (136, 137). Only recently it has been shown that 
free nsP1 facilitates the release of virus particles by antagonizing the effects of 
the cellular antiviral protein tetherin (138). NsP1 is also the most stable 
alphavirus nsP and contributes to the stabilization of other nsPs in infected cells, 
which most likely occurs via the interactions that take place in the RC (139). It 
is likely that nsP1 also interacts with a number of cellular proteins, although 
their identities have not been revealed, in part because no alphavirus vectors 




NsP2 (~90 kDa) is the largest alphavirus nsP. It has multiple known enzymatic 
activities as well as many non-enzymatic functions. The N-terminal region 
(aa residues 1–470) of nsP2 has functions important for viral RNA synthesis 
and modifications, including RTPase and nucleoside triphosphatase (NTPase) 
activities (134, 140, 141). The ability of nsP2 to function as an RNA helicase 
has also been predicted (142). However, truncated versions of nsP2 lack this 
activity (140, 143), and only the full-length nsP2 of SFV (144) or CHIKV (143) 
are capable of unwinding dsRNA in 5’–3’ direction. In addition, nsP2 was 
shown to have RNA matchmaker activity; again, only full-length nsP2 has this 
property. Thus, interaction(s) between different regions of nsP2 is absolutely 
required for some of its activities (RNA helicase, matchmaker) and greatly 
stimulates other (NTPase) activities (143). However, the significance of RNA 
helicase activity is not known. It is assumed that this activity may be required to 
unwind RNA secondary structures or dsRNAs formed during viral RNA repli-
cation. It has been proposed that nsP4, which synthesizes RNA in the 5’–3’ 
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direction, and nsP2, which unwinds dsRNA in the same direction, likely act in a 
coordinated manner (143). RNA helicase activity is fueled by the NTPase 
hydrolysis activity of the same protein (141, 143, 144), and the same active site 
is also needed for RTPase activity (145). As a result, it is currently not possible 
to study the significance of these reactions for alphavirus separately from each 
other. Recent data suggest that these activities are absolutely required for RNA 
replication and that no RNA synthesis or RC formation takes place in their 
absence (108). Very recently, it was also shown that nsP2 and nsP4 together 
regulate replication fidelity of alphaviruses and that viruses can alter their RC 
fidelity to overcome intracellular nucleotide-depleting conditions (146).  
A papain-like protease domain as well as an enzymatically nonfunctional 
methyltransferase-like domain (MTL) can be found in the C-terminal region of 
nsP2, which is the only part of nsP2 with resolved 3D structure (147). The pro-
tease activity of nsP2 is essential for the correct processing of the virus ns 
polyproteins, and it therefore coordinates the replication of the viral genome 
(148). The cleavage of the P1234 is very well regulated and involves both 
recognition of short cleavage-site sequences and presentation of these sites to 
the protease (149). The catalytic site of the protease is able to cleave the 
nsP3/nsP4 junction (hereafter 3/4 site) and the 1/2 site in cis (90, 148). In addi-
tion, the 3/4 site of SFV can be efficiently cleaved in trans. In contrast, the 2/3 
site can be processed only in trans (90) because the nsP2 molecule sterically 
cannot cleave its own C-terminus (147). It has also been shown that, unlike 
other cleavage events, the processing of the 2/3 site of SFV requires a full-
length nsP2 protease with an authentic N-terminus as well as a precise assembly 
of the cleavage complex. Even small changes in the N-terminus of the enzyme 
are poorly (or not at all) tolerated. Moreover, for cleavage of the 2/3 site, the 
region located ~165 aa downstream of the cleavage site (at the end of the  
N-terminal macro domain of nsP3) is absolutely required (97). Thus, other 
domains and structural configurations of nsP2 as well as other nsPs modulate 
the protease activity of the protein.  
As noted above, the C-terminus of nsP2 also contains an MTL domain that is 
apparently nonfunctional as a methyltransferase because of the absence of a 
number of crucial structural elements (147). However, this region is essential 
for alphavirus replication: it has been reported to have roles in the regulation of 
negative-strand RNA synthesis and in the induction of cytopathic effects, which 
differentially modulate host defense mechanisms (150) (for more details, see 
2.4 and 2.5 and publications I, II, III). Indirect data indicate that this region 
likely interacts with the N-terminal region of nsP2; clearly, its presence is 
crucial for the RNA helicase activity of nsP2 (143). 
NsP2 proteins of Old World alphaviruses also have nuclear functions, 
including the shutdown of cellular transcription and the inhibition of type I IFN 
signaling (see 2.4 for details and references). For this, part of the nsP2 mole-
cules localize to the nucleus of an infected cell. For SFV, the nuclear locali-
zation of nsP2 was originally proposed to be mediated by a canonical nuclear 
localization signal (NLS) located in the C-terminal region of the protein (151). 
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Mutation in this element blocks nsP2 translocation to the nucleus and remark-
ably reduces the ability of the virus to counteract the induction of type I IFN 
(152, 153). Mutations of this site also reduce the pathogenicity of SFV infection 
for mice (154). However, the mutations in the proposed NLS interrupt the 
nuclear transport of nsP2 only at +37oC and not at +28oC (153); concordantly, at 
reduced temperature this SFV mutant is fully capable of counteracting the type I 
IFN response (publication IV). Furthermore, none of the NLSes that have been 
predicted for the nsP2 of SINV have any role in the nuclear transport of the 
protein (155), and no classical NLS has been predicted in nsP2 of CHIKV. 
These data are more supportive of the idea that there is no true NLS in 
alphavirus nsP2. If this is the case, then mutations in the “NLS” of SFV most 
likely act by disturbing the conformation of the protein under normal (but not 
low) temperature. In short, it is not clear how the nuclear transport of nsP2 
actually occurs.  
NsP2 is also central for induction of shutdown of host cell translation. This 
process is different and independent from induction of shutdown of host cell 
transcription. However, the molecular details of this process are poorly under-
stood because shutdown of host-cell translation is caused by several different 
mechanisms (156, 157).  
Given its roles in the inhibition of host cell transcription and translation, it is 
not surprising that nsP2 is the most important factor causing the cytotoxicity 
associated with Old World alphavirus infection in vertebrate cells. Even the 
expression of nsP2 as an individual protein leads to shutdown of cellular tran-
scription and translation (157, 158). Mutations in the C-terminus of nsP2 are 
often responsible for persistent alphavirus infection or for prolonged survival of 
infected vertebrate cells (159–161). A key feature of these mutants is their 
inability to inhibit host cell transcription (158, 162). The best-characterized 
mutation responsible for imparting a noncytotoxic phenotype to Old World 
alphavirus replicons has been mapped to the MTL domain. The residue affected 
is proline 726 (Pro726) in the case of SINV (158–160) or Pro718 in the case of 
SFV or CHIKV (153, 163). For SINV, this mutation reduces viral RNA repli-
cation levels and renders nsP2 unable to shut off host-cell transcription and 
translation. In the context of SFV replicons, substitution of Pro718 with a Gly 
residue reduces but does not completely eliminate their cytotoxic properties 
(153). In the case of CHIKV of the WA genotype, the effect of the Pro718 to 
Gly mutation is similar to that observed for SFV (163); however, as shown in 
the Results and Discussion section, this does not fully apply to CHIKV of the 
ECSA genotype (see 4.1). In addition, such cytotoxicity-reducing mutations in 
nsP2 result in reduced stability of late RCs as well as moderate to severe reduc-
tion of viral RNA synthesis and continuous negative-strand RNA synthesis in 






NsP3 (~60 kDa) can be divided into three domains of roughly similar length: 
the N-terminal macro domain, the central zinc-binding domain (ZBD; also 
known as AUD – alphavirus unique domain) and the C-terminal hypervariable 
domain (HVD), which is predicted to be intrinsically unstructured (112). 
Historically, the role of nsP3 in alphavirus infection has been less obvious than 
the roles of the other nsPs. Surely, nsP3 is needed for RNA replication; fur-
thermore, it has been shown to be the main determinant of SFV neurovirulence 
(164, 165). However, this protein has no relevant enzymatic activity, and with 
exception of its N-terminal macro domain, it shows no similarity with proteins 
from other viruses or organisms. 
Macro domains are widely distributed throughout all eukaryotic organisms 
as well as bacteria and archaea, indicating an important basic biological func-
tion (166). Such domains are also found in the nsPs of several positive-strand 
RNA viruses, including hepatitis E virus, rubella virus and coronaviruses (1). 
The crystal structures of the macro domains of CHIKV, VEEV and SINV have 
been determined (167, 168). The alphavirus macro domain can bind RNA, 
poly(ADP-ribose) and ADP-ribose. It has been assumed that RNA binding 
might be the main function of the nsP3 macro domain in viral genome repli-
cation (167, 169, 170). In addition, macro domains of several alphaviruses 
exhibit very weak ADP 1’-phosphate phosphatase activity (167). This activity is 
not universal (the macro domain of SFV lacks this activity) (169) and cannot be 
logically connected with any known process occurring during alphavirus infec-
tion. This has led to the suggestion that this activity is not important for the viral 
lifecycle and most likely represents a consequence (or side effect) of another, 
currently unknown, enzymatic activity of the macro domain. It may be linked to 
the ability of nsP3 to bind poly(ADP-ribose) – a molecule added to numerous 
proteins by poly(ADP-ribose) polymerases. IFN-induced poly(ADP-ribose) 
polymerases have been shown to act as potent inhibitors of alphavirus infection 
(171); hence, it is logical to assume that alphaviruses may have a mechanism 
that counteracts the antiviral activity of these proteins. It is also clear that the 
macro domain interacts with other nsPs (97, 168). These interactions are 
important for the viral life cycle; for example, it has been shown that the C-
terminal region of the macro domain has a role in ns polyprotein processing. 
Currently available data suggest that the macro domain is needed for the precise 
positioning of the cleavage site in the P23 precursor relative to the active site of 
the nsP2 protease to provide access (and cleavage) to the previously unexposed 
site (97).  
The central domain of nsP3 is conserved among alphaviruses (7). This 
region was crystallized as part of a fragment of P23 and has been shown to bind 
zinc ions, which led to its name (ZBD). Mutational studies have revealed that 
this function is crucial for viral infectivity. In addition, its 3D structure suggests 
that this region participates in RNA binding and may assist the macro domain in 
this process (168). Beyond this, very little is known about the role of the ZBD. 
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A recent study found that a defect caused by the swapping of regions down-
stream of the ZBDs of SFV and CHIKV, was rescued by a second-site mutation 
located in the ZBD (112). These data indicate that the ZBD and HVD of nsP3 
interact with each other and that this interaction is crucial for functional RC 
formation. It has also been recently shown that nsP3 is involved in the stabili-
zation of nsP4 (164).  
The C-terminal HVD is highly variable in length and sequence. However, it 
does contain some conserved motifs that are shared between few, many or all 
alphaviruses. As this region is intrinsically unstructured, it is also tolerant to 
different deletions as well as marker-protein insertions (41, 172). Based on the 
unstructured regions of other viruses, it can be assumed that the HVD interacts 
with multiple cellular proteins. Thus far, the most studied interaction is the 
binding of the nsP3 of Old World (but not New World) alphaviruses to G3BP 
proteins (or to Rasputin, a G3BP homolog in mosquito cells). This event 
inhibits the formation of stress granules during SFV, CHIKV and SINV infec-
tion (173–177, 87). Cellular stress granules are induced by many types of envi-
ronmental stressors and act as a translational silent storage unit for mRNA. 
They are also induced by viruses and possibly function in cellular antiviral 
defense (178). Indeed, SFV lacking ability to inhibit stress granule formation is 
attenuated (173). Interestingly, however, the depletion of G3BP proteins from a 
cell also inhibits alphavirus replication (87), indicating that these proteins also 
have some proviral functions. In addition, a proline-rich motif within the HVD 
has been demonstrated to interact with amphiphysins. These interactions were 
shown to promote viral replication; however, the mechanism was not described 
(179). Clearly, the list of cellular proteins capable of interacting with HVD will 
continue to expand.  
The N-terminal region of HVD is phosphorylated at multiple serine and 
threonine residues. It has been shown that SFV mutants that are totally defective 
in nsP3 phosphorylation remain viable but exhibit a decreased rate of RNA 
synthesis and reduced pathogenicity in mice (180). The significance of nsP3 
phosphorylation for RNA replication has also been demonstrated for SINV 
(181). In SINV, the phosphorylation of the HVD plays a role in negative-strand 
synthesis (182). In the case of VEEV, the phosphorylation of this region is 
important for virus replication in insect cells but not in vertebrate cells (172). It 
has been assumed, but not directly demonstrated, that HVDs of other 
alphaviruses are similarly phosphorylated. Very recently, it was demonstrated 
that SFV, but not CHIKV, infection causes hyper-activation of the PI3K–Akt–
mTOR pathway. The functional determinant for this activation was the HVD of 
SFV nsP3. Furthermore, the sequence elements required for the hyper-acti-
vation of the PI3K–Akt–mTOR pathway seemed to overlap with the phos-
phorylation region; however, nsP3 phosphorylation itself was not required. 
Interestingly, the ability to hyper-activate the PI3K–Akt–mTOR pathway cor-
related perfectly with the ability of viruses and their mutants to drive RC inter-




The RNA-dependent RNA polymerase (RdRp) activity of alphavirus replicase 
is located in the nsP4 (~70 kDa). The large C-terminal region of this protein 
contains a conserved GDD motif that is characteristic of viral RNA polymerases 
(183) and most probably has a 3D structure that is similar to other RdRps. The 
N-terminal region of nsP4 (~100 aa residues) is unique (conserved only among 
alphaviruses) and may lack a fixed 3D structure (184). 
Compared to other nsPs, the amounts of nsP4 present in alphavirus-infected 
cells are relatively low. One reason for this is the presence of an opal termi-
nation codon located upstream of the nsP4-encoding region. This codon is pre-
sent in most alphaviruses, and terminator read-through of this region occurs 
with only 10–20% efficiency (7). Another reason for the low abundance is an 
absolutely conserved N-terminal tyrosine residue that, according to the N-end 
rule, acts as a destabilizing aa residue (185). This results in rapid degradation of 
free nsP4; however, nsP4 proteins included in RCs are protected from degra-
dation (186). Although nsP4 is directly responsible for the synthesis of viral 
RNAs, other nsPs are also required for this activity (187). The N-terminal Tyr 
residue in nsP4 (and possibly N-terminal domain of nsP4 as well) is involved in 
interactions with nsP1. These interactions are crucial for negative-strand RNA 
synthesis and are interrupted if the Tyr is replaced with a nonaromatic aa resi-
due (188). The interaction between nsP4 and nsP1 is believed to be important 
for the formation of RCs (128, 189). Mutations introduced into the presumably 
unstructured N-terminal region of nsP4 have resulted in defects in negative- or 
positive-strand RNA synthesis (184). Additionally, nsP4 has also been sug-
gested to interact with host protein components that modulate viral RNA repli-
cation (184, 190). 
The expression of functional full-length nsP4 as a soluble recombinant pro-
tein has been extremely difficult to achieve. However, the expression and isola-
tion of SINV nsP4 was achieved by truncating the N-terminal portion of the 
protein (Δ97nsP4). In vitro studies using Δ97nsP4 showed a lack of RdRp 
activity. However, the recombinant protein was shown to possess terminal 
adenyltransferase activity. This function is apparently needed for the synthesis 
of the poly(A) tail on positive-strand RNAs (54, 191). RdRp activity was 
detected only for the full-length recombinant nsP4 of SINV (187), indicating 
that the presence of the N-terminal region is crucial for this activity. To perform 
RNA replication, nsP4 should be able to bind CSEs in the viral genome; this 
function may be assisted by other nsPs. The requirements for the recognition 
and binding of different CSEs differ from each other. Thus, purified nsP4 is 
capable of performing synthesis of full-length negative- and positive-strand 
RNAs but not SG RNAs (192). This can partially be explained by the fact that 
nsP4 recognizes different CSEs using different aa motifs. Thus, motif required 
for recognition of the genomic promoter in the negative-strand RNA spans from 
nsP4 aa residue 531 to aa residue 538. In contrast, a peptide fragment that con-
tained a sequence corresponding to aa residues 329–334 of nsP4 (presumably 
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corresponding to the fingers domain of RdRp) was found to be essential for 
binding to the SG promoter. In both cases, however, the binding of nsP4 to 
promoter sequences required the presence of other nsPs (193, 194).  
 
 
2.4 Recognition of alphavirus infection by cell and viral 
counteraction to cellular defense mechanisms 
Mammals have evolved elaborate defenses to fight infections by viruses. A 
large number of gene products capable of suppressing alphavirus infection can 
be expressed in response to a viral infection. However, the products of such 
genes are often rather harmful to host cells (195), preventing their continuous 
expression. Conversely, the window of opportunity for a host cell to counteract 
alphavirus infection is quite small – within a few hours, an alphavirus will 
overtake a host cell, which then becomes unable to respond to subsequent IFN 
treatment (196). Thus, the success or failure of a cell to respond to a viral infec-
tion depends on early recognition of the infection. 
Cells are capable of recognizing pathogen-associated molecular patterns 
(PAMP) using various pattern recognition receptors (PRRs). The most common 
PAMPs associated with infection of RNA viruses are abnormal (from the 
cellular standpoint) RNA molecules, such as dsRNAs and RNAs lacking cap-
structures at their 5’ ends. Such molecules can be recognized by membrane-
bound receptors such as Toll-like receptors and cytosolic RNA helicases as well 
as by different effector proteins such as protein kinase R (PKR). All these 
molecules have been shown to have some role in limiting alphavirus infection 
(197, 198). However, recent data clearly indicate the leading roles of cytosolic 
helicases, retinoic acid-inducible gene 1 (RIG-I) and melanoma differentiation-
associated protein 5 (MDA-5) in this process (199). Interestingly, there is con-
siderable discrepancy regarding which of these proteins is the key factor for the 
detection of alphavirus infection (199–201). There are also important differences 
in the PAMPs that are recognized by these receptors. MDA-5 recognizes long 
(>4 kbp) dsRNAs (202), such as the dsRNA replication intermediates of 
alphaviruses. RIG-I can also recognize long dsRNA molecules; however, it also 
recognizes ssRNA molecules that contain a triphosphate structure at the 5’ end 
(203) as well as short dsRNAs in which at least one RNA strand has a 5’ 
triphosphate structure (204). While the recognition of short dsRNA duplexes by 
RIG-I requires the presence of a 5’ triphosphate, this element is not needed for the 
recognition of dsRNAs with a length >200 bp (205). Alphaviruses have been 
shown to produce all of the above types of PAMPs: they produce long dsRNAs 
during the replication of their RNA, uncapped ssRNAs during the infection (44) 
and partially double-stranded RNAs harboring 5’ triphosphates due to the ability 
of their replicases to bind and copy cellular RNAs (publication IV). 
Activated RIG-I and MDA-5 both signal via mitochondrial antiviral sig-
naling protein (MAVS). The activation of MAVS in turn activates several 
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downstream effectors, including interferon regulatory factors (IRFs) 3 and 7 
(206, 207), which enter the nucleus and activate the expression of several cel-
lular defense molecules, including type I IFNs (Fig. 6). It has been shown that 
the expression of antiviral genes in response to RIG-I activation is sufficient for 
the suppression of CHIKV replication, without the need for further ampli-
fication of the response (208). However, the secretion of type I IFN activates 
auto- and paracrine IFN signaling, resulting in the amplification and spread of 




Figure 6. Simplified scheme of the induction of type I IFNs during alphavirus 
infection. Upon alphavirus infection, the viral replicase is responsible for the synthesis 
of dsRNA replication intermediates and, depending on virus, short partially dsRNAs (at 
least one RNA strand has a 5´ ppp structure) and viral ssRNAs with 5´ ppp structures. In 
immunocompetent cells, these PAMP molecules are recognized by the cytoplasmic 
pattern recognition receptors RIG-I and MDA5 (blue). Activated receptors initiate sig-
naling through MAVS (an adaptor protein on the mitochondrial membrane), resulting in 
the activation of the transcription factors IRF3 and IRF7 (yellow). The activated tran-
scription factors translocate into the nucleus, where they activate the expression of type 
I IFN genes, resulting in the production and secretion of IFN (violet). IRF3 and IRF7 
also activate the transcription of other antiviral genes; similarly, the binding of type I 
IFN to its receptor on the cell surface results in additional signaling and leads to the 
amplification of the antiviral response (not shown). 
36 
As alphaviruses produce large amounts of PAMPs, they must be easily recog-
nized and thus vulnerable to host defenses. However, viruses in turn have 
acquired counter-defenses that allow them to exist and continue to infect 
mammalian hosts. The simplest and most robust counter-defense is to rapidly 
shut down a host cell after infection and to produce progeny virus very quickly 
(7). The suppression of host cell gene expression also allows alphaviruses to use 
all cellular resources and metabolic pathways for their replication. Thus, it is 
not surprising that alphaviruses can effectively inhibit both host cell transcrip-
tion and translation through separate mechanisms (157).  
Transcriptional shutdown is essential to limiting the production of antiviral 
proteins, including type I IFNs, that play a role in the early innate immune 
response and represent a first-line defense mechanism against viral infection 
(152, 209). The virus also benefits from the shutdown because the capacity of 
the infected cell to signal to surrounding cells via type I IFNs and other cyto-
kines is reduced, thus expediting virus propagation (157, 209). Old World 
alphaviruses use nsP2 to inhibit cellular transcription (158, 210). During the 
early phases of infection, nsP2 inhibits cellular transcription by inducing the 
rapid degradation of Rpb1, which is the catalytic subunit of the RNA poly-
merase II complex. Unlike picornaviruses, where viral proteases directly cleave 
their cellular targets, the protease activity of nsP2 does not play a major (or 
maybe any) role in this degradation; instead, nsP2 somehow induces the 
ubiquitination of Rpb1. Because Rpb1 is the subunit that catalyzes the poly-
merase reaction during RNA transcription, its degradation prevents both 
ongoing transcription and activation of cellular genes. Moreover, complete 
degradation of Rpb1 occurs before any other virus-induced change; therefore, it 
has been proposed that the degradation of Rpb1 is the first and most critical step 
in the down-regulation of the cellular antiviral response (210). Interestingly, 
New World alphaviruses use very a different mechanism to down-regulate 
cellular transcription. Their capsid proteins have both NLSs and nuclear export 
signals (NESs), respectively allowing them to bind to importin α/β and the 
nuclear export receptor RCM1. Thus, the capsid protein of these viruses forms 
complexes that accumulate at the nuclear pores and inhibit nuclear-cytoplasmic 
traffic, causing transcriptional shutoff (211). Interestingly, the capsid proteins of 
Old World alphaviruses, such as CHIKV, also contain both NLS and NES ele-
ments and traffic between the cytoplasm and the nucleus (212). The role and 
significance of this process for CHIKV infection are currently unknown. 
In addition to the repression of overall gene expression, it has been shown 
that Old World alphavirus infection can also specifically inhibit the induction 
and expression of antiviral genes. This may be achieved by specific suppression 
of type I IFN expression (152) and/or by inhibition of IFN signaling. Indeed, 
some alphavirus strains, including those of CHIKV and SINV, have been shown 
to inhibit type I IFN-mediated signaling by interfering with the JAK/STAT1 
(signal transducer and activator of transcription) pathway (213, 214). Inhibition 
of STAT1 phosphorylation and/or nuclear translocation is also an important 
determinant of alphavirus virulence (214, 215). Interestingly, the main factor 
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responsible for both of these effects is nsP2. In SINV mutants, the determinant 
of virulence was mapped to the 1/2 site of P123, suggesting that the critical 
factor determining a nonvirulent/virulent phenotype may be the release of nsP2 
from the ns polyprotein. The significance of this event was highlighted by using 
a SINV mutant that was unable to process the P123 polyprotein (95). As studies 
describing the general shutdown of transcription, the specific shutdown of IFN 
expression, and the inhibition of IFN signaling mediated by nsP2 have been 
performed in different laboratories using different viruses and different cell 
lines, it is difficult to conclude whether these are all independent mechanisms or 
whether they represent different facets of the same process. However, as the 
elements of nsP2 that are required for the induction of the general shutdown of 
transcription and for the inhibition of STAT1 signaling are different (158, 163), 
it is likely that these processes (though mediated by the same protein) are dif-
ferent from each other. Thus, multiple mechanisms (including both general and 
more specific mechanisms) may be involved in the inhibition of type I IFN 
expression/signaling. 
NsP2 also induces the shutdown of host cell translation. The molecular 
details of this event are not well understood because the shutdown of host cell 
translation is caused by several different mechanisms (156, 157). However, it is 
clear that alphaviruses use, at least in part, cell’s own defense mechanisms to 
achieve this shutdown. The inhibition of translation in virus-infected cells is 
probably an ancient host defense mechanism that aims to block viral multi-
plication. In vertebrate cells, dsRNA-activated PKR, the expression of which is 
activated by type I IFN, is one of the key regulators of protein translation. Viral 
dsRNA induces strong PKR activation, which leads to the phosphorylation of 
the translation initiation factor eIF2α and to the inhibition of translation initia-
tion in alphavirus-infected cells (156, 157). Therefore, similar to many other 
viruses, alphaviruses have developed ways to circumvent this mechanism 
and/or to use it for their own benefit. For example, the translation of SINV SG 
RNA does not depend on eIF2α, as it (similar to the SG RNAs of some other 
alphaviruses) contains a highly stable RNA hairpin loop (a translational 
enhancer) located downstream of the initiation codon. This structure can stall 
the ribosome on the correct site to initiate the translation of SG RNA, thereby 
bypassing the requirement for a functional eIF2α and facilitating continuous 
viral protein synthesis despite the presence of PKR activity (216, 217). 
Another pathway leading to eIF2α phosphorylation and translation shutdown 
in alphavirus-infected cells is the unfolded protein response (UPR) in the ER 
(197, 218). The UPR offers a defense against high concentrations of misfolded 
proteins in the ER. The alphavirus glycoproteins E1 and E2 are expressed, pro-
cessed and modified in the ER, where their quantities likely exceed folding 
capacity, leading to the accumulation of their unfolded forms. This is sensed by 
protein kinase R-like endoplasmic reticulum kinase, which then becomes acti-
vated and phosphorylates eIF2α, resulting in the repression of protein trans-
lation (218, 219). At least two different proteins have been shown to inhibit the 
UPR in CHIKV-infected cells: nsP4 (220) and nsP2 (221). Thus, alphaviruses 
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have multiple ways of triggering host defenses and also possess multiple means 
to counteract them or even to use them to their own advantage.  
 
 
2.5 Alphavirus-based vector systems 
The alphavirus genome is extremely amenable to genetic manipulation due to its 
small size and the existence of full-length infectious viral cDNA clones. Most 
vectors based on alphaviruses have been constructed for one of the following 
purposes: 1) for basic research efforts investigating the virus itself or 2) for use as 
biotechnological tools, in vaccine development or in gene therapy. There are 
different ways to classify alphavirus-based vectors. One possibility is to divide 
them into two basic categories, namely, replicon vectors and full-length 
replication-competent vectors, which are respectively based on the absence or 
presence of the structural region in the genome of the vector. In both of these 
systems, the viral replicase is produced from a replicating RNA template. 
Recently, a completely different approach has been applied: the replicase has 
been expressed from non-replicating mRNA transcribed from a standard 
(plasmid) expression vector, while replication-competent template RNA is 
produced from other plasmid vector (e.g., it is provided in trans). Thus far, such 
systems, called trans-replicase systems, have been mostly used to study 
alphavirus replication (107, 108, 110), but they can also potentially be applied as 
genetic vaccines and/or as tools to study virus-host interactions (publication IV). 
 
 
2.5.1 Tagged alphavirus genomes 
Full-length replication-competent alphavirus vectors have been designed to 
replicate in infected cells and to trigger formation of new virions. Thus, theo-
retically, such vectors can undergo unlimited rounds of infection. Although 
such vectors can be applied in gene therapy and biotechnology, they suffer from 
a limited capacity for the insertion of additional genetic material: due to the 
icosahedral capsid, the size of genome that can be packed into the virions is 
limited. Such vectors also suffer from genetic instability due to non-proof-
reading nature of the viral RNA polymerase and, perhaps more importantly, due 
to RNA recombination coupled with the growth advantage of shorter genomes 
that have lost inserted sequences (222). Thus, such vectors are typically 
designed for and used in studies of alphavirus infection, both in vitro and in 
vivo. For these purposes, virus genomes tagged with gene(s) that encode marker 
protein(s) are especially useful. 
The simplest approach for marker gene insertion is to duplicate the sequence 
of the SG promoter and then place a sequence encoding a marker protein under 
the control of either a native or additional SG promoter (223, 224). Cells 
infected with such viruses can be easily recognized by the expression of the 
marker protein, enabling regions of virus replication to be identified in vivo. As 
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the quantification of marker protein expression is generally simpler than the 
quantification of viral proteins or the copy number of viral RNAs, the efficiency 
of virus replication (or an effect of an antiviral drug) is also easy to measure 
using markers (225, 226). However, in general, using such vectors provides 
little information about the virus replication process inside of the infected cell. 
The same applies for vectors where marker protein is expressed as a cleavable 
part of an alphavirus-encoded structural or ns polyprotein (212, 227).  
To obtain additional information about replicase proteins and/or the repli-
cation process itself, a fluorescent tag must be fused to nsP such that the tagged 
protein remains functional (ideally, the insertion should cause no functional 
defect at all). Therefore, this insertion strategy requires either the screening of 
viral genomes using random insertion mutagenesis or educated guesses based 
on known or predicted 3D structures of nsPs. It has been shown that a marker 
protein can be inserted into many positions in the HVD of nsP3 as well as in 
some other regions of this protein. Similarly, there are at least three regions of 
nsP2 that can tolerate an EGFP insertion (228, 229). In contrast, no reports of 
successful tagging of functional nsP1 are available. This is also the case for 
nsP4, although this protein has been shown to tolerate short peptide tags at its 
C-terminus (87, 230). All such recombinant viruses represent important tools 
for the study of virus-host interactions and the tracking of viral nsP and RC 
localization in infected cells (228–231). 
 
 
2.5.2 Alphavirus replicon vectors 
Alphavirus replicon vectors contain modified viral genomes in which the region 
encoding the viral structural proteins has either been removed or replaced with a 
foreign sequence. Consequently, the replicons cannot make virions and are 
therefore restricted to undergoing only a single cycle of replication (232). When 
transfected into cells, replicon RNA serves as mRNA for the viral replicase, 
which then amplifies the replicon and transcribes the SG RNA. As many types 
of cells can be infected with alphaviruses but cannot be efficiently transfected 
with large RNA molecules, a virus replicon particle (VRP) system is commonly 
used. High-titer VRP stocks can be generated using replicon and helper 
(encoding viral structural proteins) RNAs that have been transcribed in vitro 
and then co-transfected into mammalian cells (232, 233). To prevent the 
formation of infectious genomes via RNA recombination, the structural region 
of alphaviruses can be split between different helper RNAs and/or the SG pro-
moter can be removed from helper RNAs (234, 235). 
Alphavirus-based replicon vectors are widely used. Replicons expressing 
tagged nsPs or individual marker proteins are used in much the same way as 
tagged viruses; they are especially useful in cases where a lack of spread of 
infection represents a benefit. When alphavirus replicon vectors are used for 
biotechnological applications, they are characterized by high-level expression of 
foreign genes and a broad range of susceptible host cells, including those of 
insect and mammalian origin. Other characteristics include high cytotoxicity, 
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rapid death of infected cells and, for cells with an intact type I IFN response, 
high levels of IFN induction (236, 237). Depending on the application, these 
properties of replicons can either represent benefits (such as in anti-cancer 
therapy approaches or in genetic vaccination) or obstacles. 
Cell lines harboring continuously replicating viral replicon RNA can be used 
for several purposes. First, such cells can be used for the production of recom-
binant proteins. Second, they are useful for screening and analysis of inhibitors of 
virus replication. Much of the progress that has been made in the development of 
hepatitis C virus (HCV) inhibitors is owed to the development of HCV replicon 
cell lines (238, 239). Such cell lines can also be useful for alphaviruses that, 
unlike HCV, grow well in cell culture, as replicon cell lines can be used at lower 
biosafety level (BSL) conditions and/or to select specific inhibitors that affect 
virus RNA replication. New World alphavirus-based replicons lack sequences 
encoding the capsid protein, the major determinant of cytotoxicity in these 
viruses. Therefore, only minimal effort was needed to develop corresponding 
noncytotoxic vectors (240). However, wild type (wt) replicons of Old World 
alphaviruses are, similar to the corresponding viruses, highly cytotoxic (157). 
Thus, attempts to reduce the cytopathic effect of these vectors have been made. 
Conflicting data have been obtained about the cytotoxicity of alphavirus 
replicon vectors that express anti-apoptotic proteins (139, 241), and no stable 
replicon cell line has been made using this approach. A more successful 
approach is based on the introduction of point mutations into nsP2, the main 
factor responsible for the cytotoxicity of Old World alphaviruses (see 2.3.2 for 
details). Alternatively (or sometimes additionally), such mutations or combi-
nations of mutations have been obtained using the selection procedure that was 
applied in publication I. Using replicons with such mutations, it is possible to 
create stable cell lines containing persistently replicating replicon RNAs of 
SINV, SFV and CHIKV. Interestingly, in the case of SINV, a single mutation in 
nsP2 (aa residue 726) was found to be sufficient to render the corresponding 
replicon noncytotoxic and capable of generating stable cell lines (160). In SFV, 
mutations similar to those used in SINV vectors have resulted in replicons with 
cytostatic effect − infected cells can survive for a long time but are not capable 
of multiplying (153). It was later found that at least one additional mutation in 
nsP2 is needed to attenuate the SFV replicon to a level that allows for the per-
manent growth of replicon cell lines (242) and the production of high levels of 
human therapeutic proteins (243). In the case of CHIKV of the ECSA genotype, 
mutations analogous to those evaluated in SINV studies had almost no effect on 
the RNA replication and cytotoxicity of replicon vectors (see Results and 
Discussion and publications I, II and III for details). Thus, there is significant 
variation regarding the requirements for the noncytotoxic growth of replicons of 
different Old World alphaviruses. Most likely, this results from the different 
properties of the nsP2 proteins and/or the different properties of other replicase 
proteins that interact with nsP2. Furthermore, it is not known which activities of 
nsP2 are affected by mutations that allow the noncytotoxic growth of replicons 
of Old World alphaviruses.  
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3. AIMS OF THE STUDY 
A few years ago, the World Health Organization (WHO) recognized two 
viruses (rabies and dengue) as causative agents of major neglected tropical 
diseases. Then, a third virus, CHIKV, was included due to its rapid spread and 
massive outbreaks. Although CHIKV has been recognized as a major human 
pathogen, there is still no licensed vaccine to prevent and no antiviral drug to 
treat CHIKV infection. The development of efficient vaccines and antivirals 
crucially depends on our knowledge about the molecular biology of the virus. 
However, in the case of CHIKV, our knowledge is limited and fragmented. The 
successful development of antivirals also depends on the availability of tools 
needed for the screening of drug candidates as well as tools for analysis of the 
mechanism(s) of drug candidate actions. Hence, the research described in this 
thesis was focused on the development of new tools essential for studies of 
CHIKV infection. Subsequently, these tools were used for analysis of the 
molecular biology of CHIKV infection and alphavirus-host interactions.  
The studies included in this thesis had the following objectives:  
1. To develop cell culture-adapted CHIKV replicon vectors that can be used to 
screen compounds with anti-CHIKV activity. In parallel, the molecular basis 
underlying the noncytotoxic phenotype of these vectors was analyzed. 
2. To develop novel trans-replication system for CHIKV to use it for the 
development of CHIKV replicons expressing tagged replicase proteins and 
for functional analysis of the effects caused by mutations introduced into 
CHIKV replicase proteins. 
3. To use previously developed SFV trans-replicase and newly developed 
CHIKV trans-replicase systems to analyze virus-host interactions. In par-
ticular, the aim was to analyze the mechanisms by which different 
alphaviruses activate and counteract host antiviral responses. 
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4. MATERIALS AND METHODS 
The methods that were applied for the selection of CHIKV replicons with a 
noncytotoxic phenotype are provided in publications I and II. The methods 
used for the analysis of mutant CHIKV replicons in cell culture and for the 
analysis of recombinant CHIKV nsP2 proteins are described in publication II. 
Please note the same replicon is named differently in publication I (CHIKV-
NCT) and publication II (ChikvRepRluc-5A-PG); for consistency, only the 
latter name is used in this thesis. Detailed descriptions of the materials and 
methods used for the construction of the CHIKV trans-replicase system and its 
subsequent analysis in cell culture experiments are provided in publication III. 
The methods used for the analysis of type I IFN induction by SFV and CHIKV 
trans-replicases in transfected cell cultures are described in publication IV. 
Plasmids encoding the replicases of different SFV strains and their mutant 
forms were obtained and analyzed together with Sirle Saul. These procedures 
were already described in the PhD thesis of Sirle Saul (244) and are therefore 
not repeated here.  
The construction of CHIKV trans-replicase plasmids, which were used to 
generate unpublished data, was performed as follows. Plasmids for the expres-
sion of CHIKV replicases harboring a Gly534 to Val mutation (CHIKV-GV1), 
a Gly1332 to Val mutation (CHIKV-GV2), a combination of Gly534 to Val and 
Gly1332 to Val mutations (CHIKV-GV12), an Arg532 to His mutation 
(CHIKV-RH), a combination of Arg532 to His and Glu1030 to Val (residue 515 
of nsP2) mutations (CHIKV-RH-EV) or a combination of Arg532 to His, 
Glu1030 to Val and Pro1253 to Gly mutations (CHIKV-RH-EV-PG) were 
obtained using a human cytomegalovirus (CMV) promoter-based CMV-P1234 
vector (III) via site-specific mutagenesis and subcloning procedures. The 






5. RESULTS AND DISCUSSION 
5.1 Construction of noncytotoxic CHIKV replicon vectors 
and analysis of molecular defects in nsP2 associated  
with a noncytotoxic phenotype (I, II)  
5.1.1 Development of stable BHK-21 CHIKV replicon cell lines  
Although CHIKV is not transmitted by an air-borne route, its handling 
nevertheless requires significant safety measures and, in some countries, 
security measures as well. These measures are lacking in many institutes. 
Furthermore, BSL3 laboratories often lack essential high-cost equipment such 
as confocal microscopes, cell sorters etc. Hence, the development of experi-
mental systems that allow CHIKV replication studies to be conducted at a lower 
BSL is clearly useful. When this study was initiated, our institute (and uni-
versity) also lacked a laboratory suitable for working with infectious CHIKV. 
As such, the use of CHIKV replicons unable to produce infectious virions was 
the only available option. 
CHIKV replicons can be easily packed into VRPs (245). VRPs mimic a viral 
infection, but they are only available in a limited supply because VRPs do not 
propagate and their production is expensive. This considerably limits their 
usage, especially in applications requiring the infection of large numbers of 
cells. For example, for massive screening projects, hundreds of thousands 
samples typically need to be analyzed. Even if a 384-well format is used, this is 
still a very large number of infected cells. This limitation could partially be 
solved by the development of stable replicon cell lines similar to those success-
fully used for HCV studies (238, 239). However, unlike HCV, vectors based on 
wt replicons of Old World alphaviruses (e.g., SFV, SINV and CHIKV) possess 
high cytotoxicity (246). To establish cell lines that persistently contain 
alphavirus replicon RNAs and express the corresponding replicase proteins, 
modifications to the virus replicative machinery that diminish virus-induced 
cytopathic effects must be introduced (161, 163). This can be achieved through 
rational design, through the introduction of random mutations or through the 
selection of spontaneously occurring mutations that result in a desired pheno-
type. 
Thus far, all mutations known to reduce the cytotoxicity of Old World 
alphavirus replicons have a similar characteristic: they all affect the nsP2 pro-
tein, most commonly its C-terminal region (153, 161, 163, 242, 247). As the 
sequence (and especially the 3D structure) of this region is reasonably con-
served, rational design can be used. Previous studies have shown that mutations 
of Pro726 of SINV, which is in a similar location to Pro718 of SFV, or to 
nearby residues in nsP2 alter the replicon phenotype, allowing for prolonged 
(SFV) or unlimited (SINV) survival of mammalian cells harboring replicons 
with such mutations (153, 160). Based on this knowledge, we replaced the 
Pro718 residue of CHIKV (in the LR-2006-OPY1 isolate, belonging to the 
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ECSA genotype) nsP2 with Gly. This substitution, which affected the MTL 
domain of nsP2 and is hereafter referred to as the PG mutation, was introduced 
into the CHIKV replicon. Disappointingly, but not totally unexpectedly, stable 
cell lines were not obtained using this replicon. In sharp contrast to SFV (153), 
the effect caused by the PG mutation was essentially undetectable (see below). 
As a motif that is similar to the so-called NLS of SFV nsP2 (another site where 
mutations reducing the cytotoxicity of SFV replicons are located) was not found in 
CHIKV nsP2 using NLS prediction software (https://www.predictprotein.org), 
further attempts to apply rational design were abandoned. Therefore, a method 
based on the selection of naturally generated mutations that reduce the 
cytotoxicity of alphavirus replicons (161, 247) was applied.  
The principle of applied approach is simple: RdRp of CHIKV (like those of 
other RNA viruses) is an error-prone enzyme and is therefore constantly making 
random errors. In nature, this feature is used by the virus to evolve. This error-
prone RdRp produces divergent viral progeny, from which variants harboring 
changes most beneficial to existing conditions have a growth advantage (248). 
This property can be used for the selection of mutants with desired properties by 
placing a virus (or, in our case, a replicon) into conditions in which only cells 
harboring noncytotoxic replicons would survive. Briefly, a puromycin 
acetyltransferase (Pac) coding sequence was cloned under the SG promoter of a 
CHIKV replicon harboring the PG mutation (ChikvRep-PG). To visualize repli-
con-containing cells, the Pac sequence was fused to an EGFP-coding sequence 
via the foot and mouth disease virus 2A autoprotease sequence (resulting in the 
release of free Pac into the cytoplasm of replicon-containing cells). When this 
replicon was used to transfect BHK-21 cells, the vast majority of the transfected 
cells died. However, after the removal of the nontransfected cells using 
puromycin, the formation of puromycin-resistant EGFP-positive colonies was 
observed (I, Fig. 1B). The selection and propagation of these colonies followed 
by the sequencing of the corresponding replicon genomes allowed for the iden-
tification of two different combinations of mutations that were apparently 
responsible for the noncytotoxic phenotype of the replicon (II, Fig. 1A). Not 
surprisingly, the adaptive mutations were identified in nsP2. To confirm the 
functional significance of these mutations, they were back-engineered into the 
ChikvRep-PG vector. Then, BHK-21 cells that were transfected with these 
mutant replicons were subjected to a cell survival assay. This assay confirmed 
that most of the BHK-21 cells that were transfected with ChikvRep-PG RNA 
died within 72 h post transfection (p.t.); no significant difference between 
ChikvRep-PG RNA-transfected cells and wt ChikvRep RNA-transfected cells 
was noticed (II, Fig. 1A). This confirmed the initial observation that the PG 
mutation alone was not able to render the CHIKV replicon as noncytotoxic. 
However, in the presence of either of the additional combinations of mutations, 
a noncytotoxic phenotype was achieved. 
The first adaptation was represented by a combination of two mutations. 
Neither of these mutations was similar to any previously reported change asso-
ciated with noncytotoxic phenotype of alphavirus replicons. However, one of 
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these mutations, the Gly620 to Glu (hereafter referred to as the GE mutation), 
was located at the beginning of the MTL domain (II, Fig. 1A) − a region that is 
commonly altered by mutations associated with a noncytotoxic phenotype. 
Another point mutation, the Glu116 to Lys (hereafter referred to as the EK 
mutation), was identified in the N-terminal domain of nsP2. A survival test 
showed that ChikvRep-EK, ChikvRep-GE, ChikvRep-EK-GE and ChikvRep-
GE-PG were all cytotoxic. In contrast, cells transfected with ChikvRep-EK-PG 
or ChikvRep-EK-GE-PG survived and were dividing at 72 h p.t. (II, Fig. 1A). 
Thus, the noncytotoxic phenotypes of these replicons were caused by a combi-
nation of the EK and PG mutations. This result was surprising because other 
known mutations associated with the noncytotoxic phenotype of CHIKV repli-
con are located in the MTL domain (163). Thus, the unusual location of the EK 
mutation provides a hint that the mechanism responsible for how this mutation 
caused a noncytotoxic phenotype might be different from those of other muta-
tions. Additional studies (see below, III and section 5.2) demonstrated that this 
is indeed in the case. 
A second adaptation found in selected replicons was an insertion of five aa 
residues (Gly-Glu-Glu-Gly-Ser; hereafter referred to as the 5A mutation) 
between residues 647 and 648 of nsP2. The localization of this mutation (in the 
region corresponding to the “NLS” of nsP2 of SFV) is similar to those of many 
other mutations shown to reduce the cytotoxicity of alphavirus replicons (153, 
163, 242). However, in contrast to previously reported changes, this mutation is 
not a substitution but an insertion. Of note, we cannot explain how such an 
insertion occurred. Most likely, it is a product of recombination rather than a 
simple synthesis mistake by RdRp; however, we could not identify from where 
this sequence originates (except that it is not derived from the replicon itself). 
As the site (though not the nature) of this mutation is clearly associated with a 
noncytotoxic phenotype of alphavirus replicons, it was no surprise that the cell 
survival assay revealed that ChikvRep-5A-PG clearly lacked cytotoxic effect, 
although the 5A mutation alone was not sufficient to confer a noncytotoxic 
phenotype (II, Fig. 1A). It was also observed that cells containing ChikvRep-
EK-GE-PG (or ChikvRep-EK-PG) exhibited much slower growth compared to 
cells containing ChikvRep-5A-PG. Consistent with these results, the fluo-
rescence produced by a marker protein was also much more prominent in cells 
containing ChikvRep-5A-PG (II). These observations are concordant with the 
hypothesis that the mechanisms underlying the noncytotoxic phenotype caused 
by the EK and 5A mutations (each combined with the same PG mutation) are 
different. 
Taken together, this part of our study revealed that noncytotoxic CHIKV 
replicons clearly differ from those of SINV, wherein individual mutations are 
sufficient to suppress replicon cytopathogenicity (155, 160). Thus, the require-
ments needed to achieve a noncytotoxic phenotype for replicons of different 
Old World alphaviruses are not identical. Furthermore, studies performed using 
replicons from CHIKV of the WA genotype revealed that when these replicons 
contained a Pro718 substitution they permitted the formation of a stable 
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noncytotoxic cell line, but only when used in combination with additional 
mutations (KR649AA or D711G) (163). Thus, more than one attenuating muta-
tion is needed to obtain stably replicating noncytotoxic CHIKV replicons. 
The presence of an easily detectable marker that is expressed from replicon 
RNA greatly simplifies the analysis of viral replication. For quantitative 
purposes, various luciferase-encoding genes are generally the most useful in this 
regard (due to their very low background levels and the large range that is 
available for measurements). However, the incorporation of a sequence 
encoding such a reporter into the replicase coding region is a major mutation on 
its own. Furthermore, such an insertion may modulate the effects of other 
mutations in an unpredictable manner. Based on these considerations, all iden-
tified mutations were also incorporated into ChikvRep-PG together with a 
Renilla luciferase (Rluc) marker fused to the C-terminal HVD of nsP3, a prefer-
able region for marker insertion in the alphavirus genome (I, Fig. 1A; II, Fig. 
1B) The BHK-21 cell line, containing persistent CHIKV replicon expressing 
Pac and EGFP (or ZsGreen) from SG promoter and containing Rluc (in optimal 
position) in nsP3 grew almost as fast as the parental BHK-21 cell line. Both 
markers were present at high and (importantly) constant levels, demonstrating 
the suitability of these cells as a safe surrogate model that could be used to 
screen anti-CHIKV compounds (I, Table 1). To date, this model has been used 
in several studies (249, 250).  
Nevertheless, there is also an obvious restriction: analyses performed using 
this cell lines are mostly limited to direct-acting antivirals that affect CHIKV 
RNA replication. At the same time, in order to be active, antiviral compounds 
do not strictly have to influence the virus directly; they can also act through host 
cell factors that are necessary for virus infection. Although many of these fac-
tors may be sufficiently similar between hamster (the source of BHK-21 cells) 
and human cells, there would also be factors that are obviously different. Hence, 
as CHIKV is a human pathogen, we also wanted to create a cell line of human 
origin containing the noncytotoxic CHIKV replicon. This cell line would be a 
more relevant tool not only for the screening of host-targeting antivirals but also 
(and perhaps even more importantly) for studies of host factors involved in 
CHIKV replication using genome-wide siRNA screens. Actually, our BHK cell 
line has recently been used for such purpose (251); however the differences in 
human/hamster sequences do clearly limit efficiency for its use. Therefore, 
whether the generated replicons were capable of persistent replication in human 
cells was also analyzed.  
Surprisingly, it was found that mutations resulting in noncytotoxic pheno-
type of CHIKV replicon in BHK-21 cells failed to produce the same phenotype 
in Huh7 (human hepatocellular carcinoma) and HeLa (human cervical cancer) 
cells. Although ChikvRep-EK-GE-PG and ChikvRep-5A-PG have somewhat 
different phenotypes, the general findings were the same: when puromycin 
selection was applied, the transfected cells stopped growing, and in a couple of 
weeks no viable cells remained (II). Originally (and mistakenly), we thought 
that the tested replicons were lethal to these cells because they were insuffi-
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ciently attenuated. This promoted further selection/adaptation experiments. For 
some unknown reason, cells transfected with ChikvRep-5A-PG RNA (without 
Rluc fused to nsP3) always died after a week or two of selection. In contrast, 
when Huh7 cells were transfected with the ChikvRepRluc-5A-PG replicon, 
puromycin-resistant colonies were obtained. Sequence analysis revealed two 
additional point mutations in the adapted ChikvRepRluc-5A-PG RNA. The first 
was found in the region encoding the C-terminal half of nsP1 (Phe391 to Leu, 
hereafter referred to as the FL mutation), while the second was found in the 
region corresponding to the beginning of the ZBD of nsP3 (Ile175 to Leu, here-
after referred to as the IL mutation) (II, Fig. 1B). These mutations have two 
properties in common: neither is located in nsP2, and both are located in the 
presumably unstructured regions that lie between the predicted domains of their 
corresponding nsPs. Thus, it became obvious that these mutations are unlikely 
classical cytotoxicity reducing mutations. BHK-21 cells are known to be 
extremely permissive to alphaviruses, allowing active viral replication and viral 
gene expression. In most other cell lines, alphavirus replication and gene 
expression occur at considerably (and often much) lower levels. Therefore, it 
seemed plausible that Pac expression by ChikvRep-5A-PG was sufficient to 
protect BHK-21 cells from the effects of puromycin but was insufficient to 
protect Huh7 cells (II, Fig. 2B, D) or other cells of human origin. Concordantly, 
a subsequent cell survival assay showed that the FL and IL mutations (either 
alone or in combination) were unable to reduce the cytotoxicity of the 
ChikvRepRluc replicon (II, Fig. 1B). In contrast, the Huh7 cell line containing 
the ChikvRepRluc-FL-5A-PG-IL replicon showed rapid growth and high levels 
of expression of the ZsGreen and Rluc reporters (II, Fig. 1B). Thus, instead of 
protecting cells from the cytotoxic effect of CHIKV replication (and/or that of 
the CHIKV replicase proteins), these mutations (FL and IL) were apparently 
needed to provide protection against puromycin and did so by activating the 
replication and transcription of noncytotoxic CHIKV replicon RNA (and thus 
the expression of Pac) in Huh7 cells (see also 5.1.2). A comparison of the 
obtained human cell line with the BHK-21 cells containing the ChikvRepRluc-
5A-PG replicon revealed that, under puromycin selection, both cell lines main-
tained similarly high levels of marker protein expression. The same was 
observed for Huh7 cells harboring the ChikvRepRluc-FL-5A-PG-IL replicon in 
the absence of puromycin selection, even after 10 passages. In contrast, in the 
absence of puromycin, reductions in ZsGreen fluorescence and Rluc activity 
were observed in the BHK-21 cell line containing ChikvRepRluc-5A-PG (II). 
This difference can also be explained by the enhanced replication of the 
ChikvRepRluc-FL-5A-PG-IL replicon, which produces more replicon RNAs 
(and replicase complexes), making their loss in the process of cell division less 
likely. Thus, a human cell line harboring a persistently replicating CHIKV 
replicon has the potential to be a convenient and safe tool for the identification 
of cellular factors involved in CHIKV replication as well as for the analysis of 
inhibitors that act through such host factors. 
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5.1.2 How do mutations in nsP2 cause a noncytotoxic phenotype? 
Despite intensive studies, the reasons for the noncytotoxic phenotypes of the 
alphavirus replicons have largely remained enigmatic. On the one hand, it has 
been shown that mutations associated with a noncytotoxic phenotype always 
reduce (sometimes severely) the synthesis of alphavirus positive-strand RNAs 
(153, 160, 163, 242). As nsPs are translated from these RNAs, their synthesis is 
generally also reduced (153, 252). On the other hand, it is assumed (though not 
always directly demonstrated) that mutations associated with a noncytotoxic 
phenotype alter some properties of nsP2, such as by modulating its enzymatic 
activity and/or altering its subcellular location. As replicase proteins (such as 
nsP2) and the synthesis of replicon RNA are coupled, it is unclear how the 
phenotype evolves: is the compromised activity of nsP2 the primary reason for 
the lack of cytotoxicity, or is the noncytotoxic phenotype caused by reduced 
amounts of nsP2 (as a consequence of reduced RNA replication)? To some 
extent, we were able to address these questions by developing a CHIKV trans-
replication system (see 5.2, III). However, initially classical approaches were 
used to analyze effect of nsP2 mutations on replicons, viruses and on nsP2 
itself. 
First, BHK-21 and Huh7 cells were transfected with mutant replicon RNAs 
that were synthesized in vitro, and the levels of positive-strand RNAs and nsP2 
were analyzed. It was confirmed that cells transfected with the noncytotoxic 
CHIKV replicons contained reduced amounts of nsP2 and replicon RNAs (II, 
Fig. 2). Similar findings have previously been shown for SFV and SINV: cells 
containing replicons with mutations enabling persistent infection synthesize 
replicon RNAs of positive polarity at significantly (sometimes >10-fold) lower 
levels (153, 160). Hence, it could be concluded that, in this regard, CHIKV is 
very similar to other Old World alphaviruses. Importantly, the results obtained 
from this analysis supported and complemented those produced in the cell sur-
vival tests. Thus, the PG mutation led to only a minor reduction in the accumu-
lation of positive-strand RNAs in BHK-21 and Huh7 cells (I, Fig. 2; II, Fig. 2A, 
B). This clearly differs from findings made using SINV (160, 252), SFV (153) 
and even CHIKV of the WA genotype (163). The replicon containing only the 
5A mutation displayed considerably reduced levels of RNA synthesis (II, Fig. 
2A, 2B), and the replicon containing 5A-PG, the main cytotoxicity-reducing 
combination of mutations, displayed significantly reduced RNA and nsP2 levels 
(II, Fig. 2A, B). The effects of the EK and the EK-PG mutations on RNA repli-
cation were even more notable: neither the corresponding positive-strand RNA 
nor nsP2 could be detected on normally exposed filters (II, Fig. 2A, 2C), indi-
cating that they were present at very low levels. Finally, the introduction of the 
FL, IL or FL-IL mutations into ChikvRepRluc or ChikvRepRluc-5A-PG 
resulted in slightly increased levels of nsP2 and SG RNAs (II, Fig. 2B, D). 
Thus, as was already hypothesized above, the FL and IL mutations act in an 
additive manner and boost SG RNA (and possibly also genomic RNA) syn-
thesis in Huh7 cells, which in turn allows synthesis of Pac at levels sufficient to 
49 
provide resistance to puromycin. The mechanisms by which these mutations 
boost CHIKV replicon replication in Huh7 cells (II, Fig. 2B, D) remain unclear. 
It could be hypothesized that these mutations somehow rearrange the inter-
actions that exist between the virus and the host cell (as shown below, these 
adaptations seem to be specific for Huh7 cells). There are several explanations 
for how this may occur, including changes in RC formation, changes in inter-
protein interactions and/or changes in interactions between viral proteins and 
host cell proteins. 
Second, the effects of the mutations described above were analyzed in the 
context of a complete CHIKV genome. Concordant with previous observations, 
the results from an infectious center assay performed in BHK-21 cells showed 
that all RNAs that contained the EK mutation had very low infectivity. More-
over, it was found that in the genomes of rescued viruses the EK mutation had 
always been reverted (II, Fig. 3). Thus, the low level of RNA replication was 
sufficient for the noncytotoxic growth of the corresponding replicon in BHK-21 
cells; however, it was not sufficient in the context of infectious virus. As 
expected, the RNA of CHIKV-PG was highly infectious, and the same was the 
case for RNAs harboring the FL, GE, IL and FL-IL mutations (II, Fig. 3). More 
interestingly, while the 5A and 5A-PG mutations resulted in similar (~10-fold) 
reduction in rescue efficiency, we were able to detect clear cytopathic effects 
only for CHIKV-5A infected cells (II, Fig. 3). This finding is consistent with 
the noncytotoxic growth of ChikvRep-5A-PG in BHK-21 cells (II, Fig. 1A). 
The combination of FL-5A-PG-IL mutations caused a major (>2000-fold) 
reduction in recombinant RNA infectivity. Thus, as the FL and IL mutations 
boosted the replication of replicon RNA in Huh7 cells (II, Fig. 2B, D), they 
may represent cell type-specific adaptations. However, this does not mean that 
they necessarily cause a reduction in RNA replication in BKH-21 cells; this 
defect may arise from a different mechanism. Concordant with this assumption, 
CHIKV-FL-5A-PG-IL was able to produce cytopathic effects, while the more 
infectious CHIKV-5A-PG was not (II, Fig. 3). Thus, it is plausible that the FL 
and IL mutations inhibited the rescue but not the RNA replication of CHIKV-
FL-5A-PG-IL. Whether this is the case could be easily revealed using the 
CHIKV trans-replication system developed in this work (described in III); 
however, such experiments have not been performed to date.  
Third, the effects of mutations on the nuclear localization of CHIKV nsP2 
were analyzed. Although the nsP2 of CHIKV lacks a putative NLS at the 
beginning of its MTL domain, it is still capable of entering the nucleus. This is 
highly important as, regardless of the exact mechanism of entry, the nuclear 
localization of nsP2 is required to turn off cellular transcription (210) and to 
counteract the interferon response (152, 209). Thus, it is also a prerequisite for 
the cytotoxic properties of Old World alphavirus replicons (155, 213). Inter-
estingly, the 5A mutation in nsP2 of CHIKV is located in a position corre-
sponding to the predicted NLS of SFV nsP2 (151), clearly indicating the 
importance of this region for the noncytotoxic phenotype of the ChikvRep-5A-
PG replicon. Initially, the effects of the introduced mutations on the subcellular 
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localization of nsP2 were studied using BHK-21 cells transfected with CHIKV 
replicons and immunofluorescence analysis. The obtained results showed that 
the presence of the PG mutation alone resulted in more prominent nuclear 
localization of nsP2 (I, Fig. 2B), whereas in cells transfected with ChikvRep-
5A-PG nsP2 was largely, but not completely, excluded from nuclei (I, Fig. 2B). 
It should be noted that these very preliminary data were included in publication 
I only upon the demand of one of the reviewers; otherwise, we would have pre-
ferred to omit these findings. The reason for our hesitation is that direct com-
parison of the phenotypes of wt and mutant replicons is difficult (actually 
almost impossible) due to the very different replication kinetics and nsP2 levels 
that they produce in transfected cells (I, Fig. 2A; II, Fig. 2). In addition, prior 
analysis performed using wt CHIKV (full virus) had already shown that the 
nuclear localization of CHIKV nsP2 is not uniform or constant over time. 
Briefly, in every preparation that was analyzed, there were infected cells where 
nsP2 was present in nuclei as well as cells where it was almost exclusively 
detected in cytoplasm. The general tendency that we observed was that the 
nuclear localization of nsP2 was more dominant at earlier timepoints of infec-
tion and less so at later timepoints. Therefore, for the next study, we repeated 
the experiments in a more systemic manner. The results obtained from these 
experiments showed that there is actually no difference between the localization 
patterns of nsP2 in cells infected with wt CHIKV or CHIKV-5A-PG (II, Fig. 
4A). We consider these data more reliable (compared to the results presented in 
I), as the replication kinetics of wt CHIKV and CHIKV-5A-PG (both are full 
viruses) are more similar to each other than those of the corresponding repli-
cons. Furthermore, for both viruses, we again observed different nsP2 locali-
zation patterns, including cells where nsP2 was predominantly located in the 
nucleus, cells where it was mainly located in the cytoplasm, and cells were it 
was found equally in both of these compartments (II, Fig. 4A). To clarify the 
matter, the localization of nsP2 was also analyzed through the fractionation of 
infected cells into nuclear and cytoplasmic fractions. This analysis revealed that 
nsP2 of wt CHIKV localized almost equally between the nucleus and the cyto-
plasm (II, Fig. 4B), similar to the nsP2 of other Old World alphaviruses (151, 
253). CHIKV-PG nsP2 behaved similarly; however, its nuclear localization was 
more extensive, as was also previously observed with SFV (153). The nsP2 of 
CHIKV-5A-PG was shown to be localized in a pattern similar to that of the 
nsP2 of CHIKV-PG (II, Fig. 4B). The analysis also confirmed that our initial 
observations from immunofluorescence analysis were correct: nsP2 was indeed 
always more abundant in nuclei at early stages of infection (II, Fig. 4B). This 
raised an interesting question: what happens to the nsP2 that is transported to 
the nucleus at early timepoints of infection? One possibility is that it is later 
transported out of the nucleus. Another possibility is that nsP2 in the nucleus is 
degraded faster than that in the cytoplasm, causing the nuclear pool of the pro-
tein to rapidly diminish once synthesis of nsP2 stops. This would represent an 
interesting topic for future studies, as we currently lack data supporting (or 
opposing) either of these possibilities. Despite this uncertainty, our results 
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clearly indicate that mutations associated with the noncytotoxic phenotype of 
the CHIKV replicon of the ECSA genotype do not hamper the nuclear locali-
zation of nsP2. Thus, the noncytotoxic effect must originate from some other 
functional defect(s) in the mutant nsP2 proteins.  
Fourth, we took advantage of a system previously developed for the pro-
duction of functional recombinant nsP2 and cell-free assays to analyze the 
multiple enzymatic activities of this protein (143). As recombinant nsP2 protein 
is rather difficult to handle (and, as it turned out, the purification and use of its 
mutant forms is even more challenging), such assays have not been performed 
in a systematic manner in any previous study. Somewhat surprisingly, it was 
found that of the two mutations that resulted in a noncytotoxic phenotype when 
combined, the 5A mutation had only a limited effect on the protease, RNA 
helicase and NTPase activities of nsP2 (II, Fig. 5B, 7, 8). In contrast, the PG 
mutation had a prominent effect on the protease and NTPase activities of the 
protein (II, Fig. 5B, 7, 8). Such behavior would have been logical for nsP2 of 
SINV or SFV harboring the PG mutation (this mutation is sufficient for or is the 
major contributor to the noncytotoxic phenotypes of the corresponding repli-
cons), but not for the nsP2 of CHIKV of the ECSA genotype, where the PG 
mutation had very limited effect on RNA replication (II, Fig. 2) and RNA 
infectivity (II, Fig. 3). This discrepancy can most likely be explained by the 
observation that in the context of P1234 polyprotein the effect of the PG muta-
tion on the protease activity of nsP2 was smaller and that no negative effects 
resulting from this mutation could be detected in cells infected with the corre-
sponding virus (II, Fig. 5). Thus, the defects caused by the PG mutation are 
most likely masked (or compensated for) when other viral (and possibly host) 
components are present. Somewhat disappointingly, no functional defect was 
exclusively found for the combinations of mutations (EK-PG or 5A-PG) that 
resulted in the noncytotoxic phenotype. Indeed, these combinations only 
resulted in a prominent (but not statistically significant) reduction in enzymatic 
activity in the case of the RNA helicase activity (II, Fig. 8C, D). One reason 
why we were unable to identify a common defect caused by these mutations 
may be very simple: such a defect may not exist. That possibility was not 
actually considered when studies I and II were performed; however, with the 
accumulation of new data (and a more critical review of older data), the possi-
bility that the mechanisms responsible for the noncytotoxic phenotypes of 
CHIKV-EK-PG and CHIKV-5A-PG are different began to appear more likely. 
Thus, the defects that cause different replicons to adopt similar phenotypes may 






5.2 Construction and use of the CHIKV  
trans-replication system (III) 
For positive-strand RNA viruses, the viral genomic RNA also acts as an mRNA 
directing the translation of the viral replicase proteins. Therefore, the expression 
of the replicase proteins is intrinsically coupled with the synthesis of viral 
genomes. Often, notably also in the studies described in the previous section, 
this limits the functional analysis of viral replicase proteins. Thus, as mutations 
in nsP2 associated with noncytotoxic phenotype of alphavirus replicon reduce 
RNA replication, the expression levels of the mutant forms of nsP2 are also 
reduced (II, Fig. 2). As already said above, this leads to the question of whether 
the noncytotoxic phenotype of such a replicon is a direct result of alterations in 
the cytotoxic properties of nsP2 and/or whether it is caused by reduced amounts 
of the protein (which is an indirect consequence because this reduction results 
from the alteration of the properties of the mutant replicase). It is not easy to 
distinguish between these possibilities. Similarly, it is not easy to compare the 
mutant replicon to the wt replicon. For this reason, our comparison led to the 
incorrect conclusion that the nuclear localization of nsP2 was reduced in the 
presence of the 5A-PG mutation (I), and a substantial amount of work was 
required to settle this issue in a later study (II). Notably, many mutations that 
are introduced into ns proteins cause genetic instability in the viral genome/ 
replicon. Such mutations cannot be studied in the context of replicating RNA 
genomes, as they always revert, pseudorevert and/or become compensated by 
secondary mutations (88, 97, 149). We have observed such phenomena when 
studying the EK and EK-PG mutations in the context of the CHIKV genome 
(II, Fig. 2A, C; II, Table 1). Thus, the development of a system in which the 
reduction (or increase) of RNA replication does not cause changes in the levels 
of replicase protein production and where mutations introduced into the 
replicase proteins cannot revert would have great value for alphavirus studies. 
It has been shown that alphavirus replicases are capable of replicating any 
suitable RNA templates provided in trans; for example, helper RNAs that are 
used for the generation of VRPs are effiently replicated and transcribed (235). 
In the replicon/helper RNA system, the viral replicase is, however, still 
expressed from self-replicating replicon RNA. As a next step toward uncou-
pling replicase expression and replicase-mediated template RNA replication/ 
transcription, we designed, constructed, tested and used a trans-replication 
system for CHIKV. This system is based on a previously described trans-
replicase system for SFV (107) but contains several improvements, such as the 
use of a codon-optimized replicase coding sequence, strong promoters to drive 
the synthesis of the template RNA used by the replicase and mRNA encoding 
the replicase itself. The basic idea of this system is simple: the expression of the 
replicase proteins must be independent of any of their enzymatic activities 
(although it may still to some degree be affected by changes in the cytotoxic 
properties of the replicase proteins, III, Fig. 8B). Only then could the effects of 
mutations affecting the ability of the viral replicase to perform RNA synthesis 
53 
be analyzed directly. In our system, the expression of replicase mRNA and 
corresponding template RNA is carried out by either bacteriophage T7 RNA 
polymerase or cellular RNA polymerase II. The design strategies used to create 
cassettes for T7 and CMV promoter-based expression of CHIKV replicase 
mRNA and to create the plasmids used for the expression of the corresponding 
template RNAs are shown in III (Fig. 1A and Fig. 1B, respectively). In trans-
fected cells, the CHIKV replicase is translated from its own mRNA but, due to 
the lack of essential cis sequences, is unable to replicate it. Instead, once syn-
thesized, the replicase finds suitable template RNA and then binds to it to trig-
ger RC (spherule) formation. This is accompanied by the synthesis of negative-
strand RNA and followed by the amplification of template RNA as well as by 
the synthesis of large amounts of SG RNA. The introduction of reporters into 
the genomic (corresponding to the ns region) and SG (corresponding to the 
structural region) regions of the template RNA (III, Fig. 1B) was hypothesized 
to provide an easy readout for replication/transcription efficiencies.  
We started our analysis by making a head-to-head comparison of CHIKV 
trans-replicases based on different promoters. The CMV promoter-based trans-
replicase system was tested in two human (Huh7, U2OS) and three rodent 
(COP-5, BHK-21, BSR) cell lines. For comparison, BSR cells (BHK-21 cells 
stably expressing T7 RNA polymerase) were co-transfected with the T7 pro-
moter-based replicase and template expression plasmids. Gaussia luciferase 
(Gluc) activity (note that the Gluc was encoded by a second ORF in the template 
RNA and thus is almost exclusively translated from the replicase-generated SG 
RNAs) and Firefly luciferase (Fluc) activity were high in all cell lines, although 
the highest levels were detected in BHK-21 and U2OS cells (III, Fig. 2A). 
However, as Fluc is encoded by the first ORF of the template RNA, it can also be 
efficiently expressed in the absence of an active CHIKV replicase. Therefore, we 
saw only a small increase in Fluc activity for the CMV promoter-based system, 
for which the inactive polymerase was used as a control (III, Fig. 2C and 2D). 
Co-transfection of BSR cells with the T7 promoter-based wt replicase and 
template RNA expression constructs resulted in levels of Fluc expression that 
were similar to those measured for the CMV promoter-based system. In contrast, 
however, when the construct expressing inactive replicase was used in T7 
promoter-based system, the Fluc expression levels were low (III, Fig. 2C). This 
may be due to the poor translation of the T7 RNA polymerase-generated template 
RNA transcripts, which lack 5’ cap structures (in contrast to CMV promoter-
derived transcripts that have 5’cap and are efficiently translated). In this regard, it 
is interesting to mention that the cap0 structure at the 5’ end of the alphavirus 
genome is also thought to be essential for replicase binding and functioning. 
While we cannot exclude the role of cap0 in this process, it is evident that the 
presence of the 5’ cap0 structure could not be an absolute requirement for 
template recognition, recruitment and replication, as RNA replication was clearly 
observed in the T7 promoter-based system (III, Fig. 3B). Comparison of the RNA 
synthesis and expression of the reporter proteins revealed very good correlation 
between Gluc activity and SG RNA levels in transfected cells (III, Fig. 2A; 
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Fig. 3B). Therefore, Gluc activity indeed serves as a good indicator of the 
efficiency of SG RNA transcription for both the CMV and T7 promoter-based 
trans-replication systems. At the same time, it was concluded that Fluc activity 
could serve as a good indicator of template RNA replication only for the T7 
promoter-based trans-replication system. The template RNA replication in the 
CMV promoter-based system was at least as powerful as that in the T7 
promoter-based system (III, Fig. 3B); however, due to high background, this 
was not clearly reflected by increased Fluc activity (III, Fig. 2).  
Trans-replication systems have been used to study the biogenesis of SFV and 
SINV replicase complexes (110, 107, 106) and for analysis of the biological 
effects of different mutations introduced into SFV replicase proteins (108). Here, 
we applied our system to study the possibility of tagging CHIKV replicase 
proteins and to analyze the effects of mutations affecting the cytotoxicity of 
CHIKV replicons on the RNA replication. There are many studies that have used 
recombinant alphaviruses carrying tags in their nsPs to evaluate various aspects of 
the viral infection cycle (111, 228, 230, 231). This is a powerful approach; how-
ever, its use is limited by the fact that tagging alphavirus replicase proteins with-
out compromising their activities is rather complicated. There are also multiple 
studies in which the functions of CHIKV nsPs have been analyzed using transient 
expression systems. While these studies are certainly very important, they suffer 
from two shortcomings. First, the functions of individual nsPs are different from 
those in the context of virus infection, where all nsPs act in coordinated manner. 
Second, expressed nsPs were often visualized using tags attached to their termi-
nus. This is a major problem, as alphavirus nsPs do not tolerate well (and some-
times not at all) modifications to their N-terminus. For example, even the presence 
of very short tags (such as a hexahistidine tag) can result in major changes in nsP 
functions – some of its activities may be severely diminished while others may be 
significantly enhanced (143). This does not mean that tagging of nsPs should be 
avoided, but rather that the data originating from such studies must be interpreted 
very carefully. However, it would certainly be ideal if tags could be inserted into 
regions where they do not alter the activities of nsP. The best test for such a system 
would be the generation of modified (tagged) viral genomes, replicases and, when 
available, trans-replicases and the demonstration that they function normally. 
Previously, our laboratory has generated multiple tagged versions of SFV 
and CHIKV genomes. Many of these have been very useful and have been 
applied in many published works (222, 225–227, 254). We have observed the 
same tendency as other researchers: only nsP2 and nsP3 allow large insertions 
in certain positions (not everywhere) (228, 229). Although successful tagging 
has been achieved, many attempts to construct tagged viruses have failed. 
Examples of the latter include the addition of EGFP to the C-terminus of SFV 
and CHIKV nsP4: such viruses could be rescued, but they were genetically very 
unstable and the inserted sequence was lost in a single passage (unpublished 
data from our laboratory). To the best of our knowledge, no group (including 
ours) has previously succeeded in tagging nsP1 in the context of functional viral 
genome or replicon. Therefore, we attempted to use our trans-replication 
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system to engineer an EGFP tag into all of the nsPs and to determine the 
reasons for the genetic instability observed in some of the tagged constructs. 
Predictably, tagging worked best in the case of nsP3. In nsP1 and nsP2, a 
marker sequence was inserted into different positions to identify an optimal 
location (III, Fig. 4A). The most suitable position (a total of 5 variants, 
including one that included a fusion to the N-terminus of nsP1, were tested) for 
the EGFP tag in nsP1 was following aa residue 516. For nsP2, the best insertion 
site was located between the NTPase and protease regions of the protein (III, 
Fig. 4B). Tagging nsP4 was the most difficult. No matter how EGFP was fused 
to the C-terminus of nsP4, the replicase activity was always severely compromised. 
This was in perfect agreement with data from experiments with corresponding 
viruses: their infectivity indicated that nsP4-EGFP is functional, while their 
genetic instability indicated that loss of the EGFP tag resulted in a huge growth 
advantage of resulting aberrant genomes. Based on this, attempts to use fluo-
rescent or luciferase (we tested several) tags in nsP4 were abandoned, and shorter 
immunological tags were used instead. Even this approach was not simple, as the 
HA-tag (Hemagglutinin-tag) invariably compromised the activity of the CHIKV 
replicase, and only the SF-tag (consisting of Streptavidin and 3×FLAG tags) 
was well tolerated (III, Fig. 4). When the tagging was performed in the context 
of CHIKV replicons or genomes, it was observed that all tags that allowed 
efficient replication in the trans-replicase system were also well tolerated in the 
context of the replicons (III, Fig. 5B). In contrast, the tags that severely reduced 
replication in the trans-replicase system invariably caused instability in the 
corresponding replicating RNAs (III, Fig. 4, 5B). Thus, the trans-replicase can 
be used to estimate whether a specific tag would work in the context of the 
viral/replicon genome. Furthermore, our analysis of tagged trans-replicases and 
a matching set of replicon vectors revealed that the tagged nsPs maintained 
characteristic subcellular localizations (III, Fig. 6). Our trans-replicases also 
enabled efficient spherule formation near the plasma membrane, confirming 
that essential steps associated with RNA replication were correctly reproduced 
in this system. In all analyzed cases, no negative effect of correctly placed tags 
(e.g., those located in positions that permitted efficient RNA replication) on 
spherule formation was observed (III, Fig. 7).  
As described in section 5.1.2, we were unable to complete functional analy-
sis of the effects caused by cytotoxicity-reducing mutations using the tools that 
were available at the time when studies I and II were performed. Hence, the 
effects of these mutations were studied using the trans-replicase system. One 
additional aspect should be taken into account while analyzing these mutations: 
in contrast to most of nsP mutations, which have little to no effect on replicase 
polyprotein production in the trans-replicase system, the cytotoxicity-affecting 
mutations are expected to have such an effect. This is not related to RNA repli-
cation (as in the context of replicons or genomes); rather, the presence of cyto-
toxicity-reducing mutations should prevent the shutdown of cellular tran-
scription/translation and allow prolonged (and thus more efficient) production 
of replicase proteins. Interestingly, an increase in nsP levels was clearly 
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observed for replicases harboring the PG mutation (III, Fig. 8B), which, on its 
own, had little effect on the cytotoxic properties of CHIKV replicons (I, II). 
The increase in nsP level was less evident for the replicase containing the 5A 
mutation, even when it was combined with the PG mutation (III, Fig. 8B). 
Interestingly, the amounts of nsP2 harboring both the 5A and PG mutations were 
clearly reduced (III, Fig. 8B), most likely because this combination of mutations 
destabilized the protein; this finding also indicates that mutations in nsP2 can 
modulate each other’s effects. Overall, despite these discrepancies, the PG and 5A 
mutations indeed resulted in effects consistent with what could be expected for 
cytotoxicity-reducing mutations. However, for the EK mutation, this clearly was 
not the case: its presence did not have any detectable effect on nsP accumulation 
(III, Fig. 8B). Once again, this indicates that the mechanism through which this 
mutation produced a noncytotoxic phenotype for the CHIKV replicon must be 
different from those of classical cytotoxicity-reducing mutations. In this regard, it 
was highly informative that the EK and EK-PG mutations in the CHIKV replicase 
drastically reduced its ability to activate Gluc expression (Gluc levels were <0.5% 
compared to those measured at the presence of the wt replicase; III, Fig. 8C). 
This result is consistent with the very low levels of replication of the 
corresponding replicon RNAs (II, Fig. 2A). Taken together, these findings clearly 
indicate that the noncytotoxic phenotype of the replicons containing the EK 
mutation represents a consequence of a severe defect in RNA replication. This 
defect led to drastically reduced nsP2 levels, which, in the presence of the PG 
mutation, were insufficient to cause cytotoxic effects in cells containing the 
corresponding replicon (II, Fig. 1). As of now, we have no evidence that the EK 
mutation actually attenuates (or eliminates) the cytotoxic properties of nsP2. In 
sharp contrast, it was observed that the PG mutation had no negative effect on the 
activity of CHIKV trans-replication (III, Fig. 8C). Thus, at the cellular level, we 
could not detect any consequences of the defects with regard to the protease, 
NTPase and RNA helicase activities of nsP2 harboring PG mutations (II). The 5A 
mutation reduced the ability of the replicase to boost Gluc expression by only 
approximately 2-fold. However, the combination of the non-cytotoxic mutations 
(5A-PG) reduced Gluc expression (compared to that of the wt replicase) by 
approximately 5-fold. This finding demonstrates that severely compromised 
replicase activity is not an absolute pre-requisite for noncytotoxic phenotype of 
Old World alphavirus replicons. In addition, this result confirms that the PG and 
5A mutations indeed affect each other: the phenotype caused by the combination 
of these mutations was different from those caused by either of them alone (II). 
Taken together, the effects of the mutations that were associated with a 
noncytotoxic phenotype in CHIKV as detected by the trans-replicase system were 
similar to those observed in the context of replicons and genomes. In the trans-
replicase system, because RNA replication does not affect replicase production, 
additional details concerning the modes of action for the cytotoxicity-reducing 
mutations were revealed. Thus, the CHIKV trans-replication system represents a 
powerful tool that can be applied for functional studies of CHIKV nsPs, replicase 
complexes and virus-host interactions.  
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5.3 Early replicases of different alphaviruses  
synthesize novel types of PAMP RNAs using  
cellular templates (IV; unpublished) 
5.3.1 The SFV replicase synthesizes novel types of PAMP RNAs  
using cellular templates 
The T7 promoter-based SFV trans-replication system has been used to reveal 
new biological properties of the virus (108, 110, 111). However, it is not the 
first alphavirus trans-replicase that has been constructed. Back in 2007, when I 
was an undergraduate student, my very first project was to work with a CMV 
promoter-based SFV trans-replicase that was constructed and tested in collabo-
ration between our laboratory and FIT Biotech Oy Plc (Finland). The aim of 
this project was to develop a new gene expression system. The constructed SFV 
trans-replicase worked well; however, it was less efficient than standard SFV 
replicon vectors. Therefore, the results of this project were only included in a 
patent application (255) and never published as an article. However, when 
experimenting with the system, researchers from FIT Biotech observed that the 
SFV trans-replicase was a very efficient inducer of type I IFN expression. As 
expected, this effect depended on the RdRp activity of nsP4; however, contrary 
to the existing paradigm, it did not depend on the presence of template RNA 
that could be replicated/transcribed by the SFV replicase. It took several years 
of hard work to reach the conclusion that RNAs of viral origin (such as dsRNA 
replication intermediates or non-capped ssRNAs) are not the only RNAs made 
by the SFV replicase that are recognized by cellular PRRs. It was shown that in 
addition to these “classical” PAMP RNAs the SFV replicase also makes large 
amounts of extremely potent type I IFN inducing RNAs using nonviral, and 
thus by definition cellular, RNAs as templates. This finding was clearly 
important, but it also contradicted the existing understanding of how alpha-
viruses (or other viruses) are recognized by an infected cell; as such, it was also 
very difficult to publish (at least in high-level journals). A repeated concern 
from such journals was regarding whether some sort of massive artifact was 
responsible for the above-mentioned observations. In other words, do these type 
I IFN-inducing RNAs also exist in cells infected with SFV? This was clearly a 
valid concern; however, it was not easy to provide a suitable answer. This was 
also the point when I (after a 5-year break) returned to the project. 
The major problem was that while we were aware of the general properties 
of nonviral PAMP RNAs, most importantly that they are relatively short and not 
polyadenylated (IV, Fig. 3), we did not know their sequences. Furthermore, we 
assumed that the sequences of these RNAs are likely to be diverse. Therefore, 
the only feasible way to prove their existence in SFV-infected cells was to 
demonstrate that RNAs isolated from SFV-infected cells maintain the ability to 
induce type I IFN expression even when all known PAMP RNAs are removed. 
In the context of SFV (and RNA viruses in general), it was believed that the 
expression of type I IFN is triggered mainly, if not exclusively, by viral ssRNA 
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containing a 5’ triphosphate and/or dsRNA produced by viral replicases during 
viral genome replication. To analyze whether this was also the case for SFV, 
mouse embryonic fibroblasts were infected with SFV4 or a noncytotoxic mutant 
(SFV4-RDR), and total RNA was purified and fractionated into polyA+ RNAs 
containing a large majority of known PAMP RNAs (including dsRNA with an 
unpaired poly(A) tail, IV, Fig. 7A) and polyA− RNAs presumably containing 
novel PAMP RNAs. Using northern blotting, it was demonstrated that the 
polyA− fraction indeed contained only trace amounts of viral negative-strand 
RNAs and no detectable negative strands of virus-derived defective interfering 
RNAs (IV, Fig. 7B). Thus, all known viral PAMP RNAs were depleted from 
this fraction. Furthermore, analysis of the infectivity of the different RNA frac-
tions revealed that polyA− RNA was also depleted (by approximately 15-fold) 
from viral positive-strand genomes. To avoid subsequent infection, both RNA 
fractions were UV-inactivated and used to transfect type I IFN competent COP-
5 cells (murine fibroblasts). As expected, the polyA+ RNA was a powerful 
inducer of type I IFN expression. However, the polyA− RNA, which lacked (or 
was strongly depleted from) known PAMP RNAs, was a quite comparable 
inducer of type I IFN expression (IV, Fig. 7C). This experiment unequivocally 
demonstrated that large amounts of previously unknown PAMP RNAs were 
indeed present in polyA− RNA fraction obtained from cells infected with SFV. 
In subsequent experiments, it was demonstrated that the properties of these 
RNAs were similar (possibly identical) to those of RNAs made in cells 
expressing SFV replicase (IV, Fig. 7D). Thus, it was conclusively proven that 
SFV replicase makes, both during transient expression and natural infection, 
large amounts of very potent nonviral PAMP RNAs. 
The discovery of this novel function of the SFV replicase led to an obvious 
question: why does a virus activate the type I IFN response in the first place? 
Type I IFN is known to mediate a wide variety of antiviral effects and repre-
sents an important first-line defense against virus infection. Our initial idea was 
that SFV simply cannot avoid nonviral PAMP production, which is to say that 
this production is simply the cost associated with the ability of the viral poly-
merase to be active in trans and/or to carry out RNA recombination with dif-
ferent RNA molecules (IV). To compensate for excessive type I IFN induction, 
alphaviruses have developed an impressive diversity of tactics to avoid IFN 
responses and/or their consequences (see 2.4 for details). Furthermore, some 
poorly understood mechanisms make SFV4 (the virus strain used in study IV) 
highly resistant to the antiviral effects of type I IFN (256). Therefore, it seemed 
that virus has developed sufficient amount of countermeasures. However, is this 
the whole truth? Are novel replicase-generated RNAs actually important for the 
viral life cycle? Although we were happy with the provided explanation, we did 
not exclude such possibilities. Furthermore, unexpectedly and rather rapidly, we 
were able to produce strong evidence supporting the above. 
Parallel studies conducted in our laboratory and summarized in the PhD 
thesis of Sirle Saul (ISSN 2228-0855; http://hdl.handle.net/10062/49532) 
revealed that SFV has two determinants of neurovirulence: the nsP3 region and, 
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interestingly, the speed of the maturation of the replicase complex (the effi-
ciency of the processing of the P123 precursor) (164). It was assumed that one 
or both of these determinants may be associated with the induction of type I 
IFN or with counteracting its antiviral effects. However, it was difficult to ana-
lyze the production of type I IFN in cell culture infected with the corresponding 
virus strains, chimeras and mutants. In contrast to the SFV mutants that showed 
reduced cytotoxicity, all of these viruses were fully capable of shutting down 
type I IFN production in the initially infected cells. Therefore, only cells that 
were primed by primary infected cells (196) and then got infected with a next 
generation of virus were able to respond by inducing type I IFN expression. It 
was, however, nearly impossible to synchronize this secondary infection using a 
panel of viruses each of which had slightly different growth kinetics. Therefore, 
the SFV-based trans-replicase constructs were generated to analyze the abilities 
of different SFV replicases and their mutants (Fig. 7A) to induce type I IFN. 
First, it was observed that replicases from nonvirulent (A7(74)) and virulent 
(SFV6; almost identical to that of SFV4, which was used in study IV) viruses 
can replicate and transcribe provided template RNA with quite similar (dif-
ferences ≤ 2-fold) efficiencies (Fig. 7B). This was expected, as the corre-
sponding viruses replicated to similar titers in cell culture (164). It also indicates 
that the ability to induce type I IFN using classical (derived from viral RNA or, 
at the case of trans-replicases, from provided template RNA) PAMPs was 
similar between the viruses. Second, the induction of type I IFN using non-
cellular PAMP RNAs (e.g. in the absence of replication competent template 
RNA) was analyzed. This analysis provided a clear answer that was completely 
opposite of what was expected. Namely, replicases from avirulent strain A7(74) 
and nonvirulent recombinant virus (SFV6-74-RE) were, in the absence of 
template RNA, poor inducers of type I IFN. In contrast, the replicase of the 
neurovirulent strain SFV6 and the replicases of all studied virulent recombi-
nants (for example, A7(74)-6-HV) were much more efficient type I IFN 
inducers (Fig. 7C). Thus, the neurovirulence of SFV clearly correlates with the 
enhanced production of type I IFN, and, consequently, almost certainly repre-
sents a consequence of some kind of immune pathology. This phenomenon is 
not completely unique in the world of alphaviruses; similar behavior has also 
been observed for SINV (257). What is unique is that the over-induction of type 
I IFN and the resulting immune pathology were clearly caused by the produc-
tion of PAMP RNAs made by use of cellular templates. To the best of our 
knowledge, this represents the first clear demonstration of the biological signifi-






Figure 7. Replicases of neurovirulent variants of SFV are powerful inducers of 
type I IFN expression. (A) Schematic presentation of the analyzed SFV replicases. 
Sequences originating from avirulent A7(74) are shown in gray, while sequences from 
virulent SFV6 are shown in white (note the switch of the nsP3 regions in the recombi-
nant viruses). The arrows above the drawings point to aa residues 534 and 1052 of 
P1234, which are responsible for the different processing speeds of the A7(74) and 
SFV6 ns polyproteins. (B, C) COP-5 cells were transfected with constructs expressing 
the indicated replicases or (B) co-transfected with the indicated replicase expression 
constructs and plasmid for the production of template RNA. The template RNA con-
tains a Gluc-encoding region under a SG promoter, allowing Gluc expression to occur 
in response to replicase-mediated SG RNA synthesis. Control cells were transfected 
under the same conditions, except that a plasmid expressing an inactivated replicase 
(harboring a GDD to GAA mutation in nsP4) was used. At 48 h post-transfection, the 
culture medium was harvested. (B) Gluc activity in the growth medium were measured 
and normalized to that measured for the control cells. The activation of Gluc expression 
serves as a measure of RNA replication and transcription, as shown in III. (C) Levels of 
IFN-β in supernatant were measured by ELISA. Data from one out of three reproducible 





5.3.2 CHIKV replicase differs from SFV replicase in the ability to use 
cellular templates for the synthesis of PAMP RNAs 
The novel PAMP RNAs made by the SFV replicase turned out to be highly 
biologically relevant. This led to the important question of whether such RNAs 
are made by the replicases of other viruses. In study IV, it was demonstrated 
that the RdRp (NS5B) of HCV makes such RNAs, which has also been 
observed in other studies (258). Properties consistent with the production of 
nonviral PAMP RNAs have also been observed for replicases from noroviruses 
(259) and picornaviruses (260). Furthermore, quite recently, it was demon-
strated that picornavirus RdRp produces molecules with biological effects very 
similar to those observed for SFV replicase-generated PAMP RNAs (261). 
Thus, the phenomenon is certainly not restricted to SFV. Therefore, it was rea-
sonable to expect that replicases of other alphaviruses would also produce 
nonviral PAMP RNAs. Here, we investigated whether this new mechanism also 
applies in the context of CHIKV trans-replicase.  
Interestingly, and very unexpectedly, it was found that the replicase of 
CHIKV is drastically different from that of SFV with regard to the above. As 
described in study III, wt CHIKV replicase was very efficient in template RNA 
replication/transcription in many cells, including type I IFN-competent COP-5 
cells (Fig. 8B). Nevertheless, in COP-5 cells, the replicase failed to induce type 
I IFN production in a template-independent manner (Fig. 8C). Based on the 
lessons learned when conducting study IV and on data from several publi-
cations (163, 213), it was first assumed that nsP2 of CHIKV might be an 
extraordinarily efficient inhibitor of type I IFN production/signaling. Therefore, 
the experiment was repeated using a panel of CHIKV trans-replicases harboring 
previously described noncytotoxic mutations (II, Fig. 8A). As previously 
observed, these mutations had various effects on the ability of CHIKV replicase 
to replicate/transcribe template RNA (III, Fig. 8C). This was also true in COP-5 
cells, except that the replicase harboring the PG and 5A mutations was strongly 
attenuated in these cells (Fig. 8B). However, even though replicases harboring 
PG or 5A mutations were efficient in RNA replication/transcription (Fig. 8B), 
they were still virtually unable to induce IFN-β synthesis in a template-inde-
pendent manner (Fig. 8C). Thus, the problem was apparently not an efficient 
counteraction of type I IFN response. Instead, it was concluded that CHIKV 
replicase simply does not make non-viral PAMP RNAs that can trigger type I 
IFN production. However, very weak type I IFN induction (nowhere near that 
achieved by the SFV replicase; ~3000 pg/ml, Fig. 8E) was observed for the 
replicase harboring both the PG and 5A mutations (Fig. 8C). It was therefore 
hypothesized that weak but detectable type I IFN induction might originate 
from the compromised protease activity of mutant nsP2, leading to the stabili-
zation of ns polyproteins that was observed in cell-free system (II, Fig. 5B). 
Stabilization of ns polyproteins, as we have shown for SFV, correlates with type 
I IFN induction (Fig. 7C). Could the same process, i.e., the stabilization of ns 
polyproteins, also create the new (for CHIKV replicase) function of non-viral 




Figure 8. CHIKV replicase cannot synthesize non-viral PAMP RNAs; however, 
such activity can be generated by the introduction of mutations affecting the pro-
cessing of the 1/2 site of P1234 (A) Locations of mutations affecting P1234 processing 
in the CHIKV ns polyprotein. (B, D) Abilities of CHIKV replicase and its mutant forms 
to replicate and transcribe template RNA and (C, E) to induce IFN-β production in a 
template-independent manner. (C, E) COP-5 cells were transfected with the indicated 
replicase expression constructs or (B, D) co-transfected with replicase expression con-
structs and a plasmid for template RNA expression (CMV-Fluc-Gluc, III, Fig. 1B). 
Control cells were transfected with a plasmid expressing an inactivated ns polyprotein 
(harboring a GDD to GAA mutation in nsP4). At 48 h post-transfection, culture media 
were harvested. (B, D) Gluc activity in the growth medium was measured and nor-
malized to that measured for the control cells. (C, E) Levels of IFN-β in supernatant 
were measured by ELISA. Data from one out of three reproducible independent 




The processing determinants for CHIKV P1234 are similar to those for P1234 
of avirulent SFV A7(74): position P4 in the 1/2 cleavage site is occupied by an 
Arg residue (His in virulent SFV6), while position 515 of nsP2 (1030 in P1234) 
is occupied by a Glu residue (Val in virulent SFV6). Mutations changing these 
residues (Arg532 to His: RH mutation; Glu515 to Val: EV mutation) were made 
and included, individually or in different combinations (including in combi-
nation with PG), into the CHIKV trans-replicase (Fig. 8A, D, E). In addition, 
mutants with inactivated cleavage sites between nsP1 and nsP2, nsP2 and nsP3 
or both were created (Fig. 8A, D, E). When the corresponding constructs were 
analyzed for the ability to replicate/transcribe template RNA, all were found 
capable of doing so, albeit to different extents (Fig. 8D). The effect of the GV2 
and RH-EV-PG mutations was minimal. The RH and RH-EV mutations 
resulted in no more than a 2.5-fold reduction in RNA replication/transcription 
(Fig. 8D). In contrast, a mutation in the 1/2 site prominently reduced RNA 
replication. Interestingly, however, the effect caused by the double mutation 
GV12 was reproducibly ~2-fold smaller than that caused by the GV1, affecting 
only 1/2 site (Fig. 8D). The most likely explanation for this observation is that 
GV12 completely prevents the cleavage of P123 into mature nsPs and thus 
locks the CHIKV replicase complex into a P123+nsP4 (early replicase) configu-
ration. Compared to the late replicase, the early replicase is clearly less efficient 
in template RNA replication/transcription. However, it still displays significant 
ability synthesize SG RNA: Gluc activity is ~130-fold over background 
(measured in the presence of inactive P1234GAA) (Fig. 8D). The GV1 mutation 
also prevents mature (late) replicase formation, but in this case P123+nsP4 
complexes could be further converted into P12+nsP3+nsP4 complexes, which 
are either not active or have lower activity than P123+nsP4 complexes. Whether 
this is true represents a topic for further studies. When all of the above replicase 
constructs were analyzed for the ability to induce type I IFN production in 
template-independent manner, clear results were obtained. The RH mutation 
(which most likely slows the cleavage of P123) slightly elevated type I IFN 
production. The effect was somewhat smaller for the combination of RH-EV 
mutations (apparently because the EV mutation accelerates P123 processing) 
and much larger for the RH-EV-PG combination (Fig. 8E). The prominent 
boosting of the effect by the PG mutation may result from the further slow 
down of P123 processing and/or from the reduced cytotoxicity of nsP2 har-
boring this mutation. The effect of the GV2 mutation was very small but still 
reproducibly detected (Fig. 8E). Again, this effect may result from altered P123 
processing (the GV2 mutation results in a nsP1+P23+nsP4 replicase that can 
synthesize both positive- and negative-strand RNAs) and/or from a reduction in 
the ability of nsP2 to counteract type I IFN signaling (P23 is not known to 
localize to the nucleus). Most drastic effects, however, were caused by the GV1 
and GV12 mutations which locked the CHIKV replicase either permanently 
(GV12) or temporarily (GV1) into its early (P123+nsP4) conformation. Both of 
these replicases induced type I IFN production at a level comparable to that 
observed for the SFV replicase (Fig. 8E). While alone this observation may still 
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be explained by a reduction in the ability of nsP2 to counteract the type I IFN 
response (P12 and P123 are attached to the plasma membrane and do not enter 
the nucleus (89)), the whole obtained dataset clearly and unambiguously indi-
cates that the production of nonviral PAMP RNAs is a property of the early, but 
not late, replicase of CHIKV. The same is almost certainly true for SFV as well, 
taking into account the data shown in Fig. 7 as well as the results obtained 
during the analysis of SFV replicases harboring numerous different mutations, 
including analogs of the GV1 and GV12 mutations (unpublished data from our 
laboratory). Thus, our results provide novel insights about the interactions that 
exist between alphaviruses and innate immune response pathways and demon-
strate that two closely related alphaviruses (SFV and CHIKV) are recognized 
differently by host cell.  
 
 
5.4 Future perspectives 
When studies described in this thesis were initiated, there was little reason to 
think that all of the topics discussed above (noncytotoxic mutations in CHIKV 
replicons, viral RNA replication, SFV and CHIKV trans-replicases and novel 
type I IFN-inducing PAMP RNAs) would ultimately come together. Further-
more, there was certainly no indication that all of this would be linked to the 
topic of the in vivo pathogenesis of alphavirus infections. However, our findings 
coalesced, and a more general picture of alphavirus biology began to emerge. 
While preparing the final publication, used in this thesis, we were able to reveal 
a number of other unique insights into alphavirus biology. This includes the 
unexpected differences found in the abilities of SFV and CHIKV to activate the 
PI3K-Akt-mTOR pathway, which is associated with the internalization of 
replicase complexes (112) and may or may not be linked to the different abili-
ties of CHIKV and SFV to induce the type I IFN response. It also includes the 
unexpected properties of CHIKV harboring EV and/or RH mutations, which 
may or may not be linked to the effects observed using the models described in 
this thesis. Although the above endeavors resulted in many unanswered in-




Based on the data obtained in the studies included in this thesis, the following 
conclusions can be made: 
– CHIKV replicons capable of persistent replication in vertebrate cell lines 
were developed. This was achieved by the selection, identification and 
analysis of different mutations located in the nsP2 protein of CHIKV. The 
noncytotoxic phenotypes of these CHIKV replicons represent a consequence 
of the functional defects caused by these mutations. Furthermore, different 
combinations of mutations causing a noncytotoxic phenotype most likely 
cause the phenotype through different molecular mechanisms.  
– Different cell lines had different requirements for supporting the 
noncytotoxic growth of the CHIKV replicon. CHIKV replicon with addi-
tional adaptive mutations in nsP1 and nsP3 that enabled its persistence in 
human cell line was constructed and analyzed. Cell lines harboring 
noncytotoxic replicons that also contained sequences encoding marker pro-
teins possessed good stability and may represent safe surrogate models for 
the screening of compounds with antiviral activity.  
– A novel CHIKV trans-replication system in which CHIKV replicase expres-
sion and template RNA replication are uncoupled was constructed. It was 
demonstrated that this system represents an excellent tool that can be used to 
analyze the effects of different mutations or tags introduced into replicase 
proteins. The unique properties of the trans-replicase make it especially use-
ful for studies of mutations that cause instability in the context of replicating 
RNA genomes.  
– Alphavirus trans-replicase systems were found to be useful tools for studies 
of virus-host interactions. The SFV trans-replicase system led to the dis-
covery of a new function of the alphavirus replicase, namely, the synthesis 
of PAMP RNAs using cellular templates. The combined use of the SFV and 
CHIKV trans-replicases, their mutant variants and the corresponding viruses 
revealed important differences in how these viruses are recognized by host 
cells. It was also found that an early alphavirus replicase is responsible for 
the synthesis of PAMP RNAs from cellular templates. The same set of 
studies revealed a connection between the ability of the SFV replicase to 
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SUMMARY IN ESTONIAN 
Alfaviiruse replikaasi roll genoomi replikatsioonis,  
viirus-indutseeritud tsütotoksilisuses ja viirusinfektsiooni 
tuvastamises peremeesraku poolt 
Alfaviirused on positiivse polaarsusega RNA genoomsed viirused, mis omavad 
laia peremeesteringi ning on võimelised paljunema erinevates rakutüüpides. 
Alfaviiruste levik selgroogsete peremeeste vahel toimub enamasti lülijalgsete 
vektorite vahendusel. Alfaviiruste perekonda kuulub ka suure meditsiinilise 
tähtsusega viiruseid nagu Chikungunya viirus (CHIKV). CHIKV infektsiooni 
iseloomustab kõrge palavik, lööve ja lihasevalu, eriti iseloomulik on aga 
liigesevalu, mis võib muutuda krooniliseks ning kesta kuid või isegi aastaid. 
Praeguseks hetkeks puudub selle viiruse vastane vaktsiin või spetsiifiline ravim, 
võimalik on leevendada vaid sümptomeid. Samas on kliima muutused ja 
ülemaailme reisimine võimaldanud CHIKV-l levida ka piirkondadesse, kus teda 
varem ei ole olnud. Näiteks jõudis CHIKV 2013. aasta lõpus Ameerikasse, kus 
tema levik on võtnud epideemia mõõtmed. Seetõttu on CHIKV uurimine küll 
intensiivistunud, kuid siiski on tema kohta käivad teadmised lünklikud ja 
ebapiisavad. Selleks, et välja töötada CHIKV vastased vaktsiinid või ravimid 
tuleb esmalt põhjalikult uurida tema molekulaarbioloogiat ja, mis veelgi 
olulisem, mõista kuidas CHIKV ja tema peremees teineteist vastastikku mõju-
tavad. Paraku on tegemist ohtliku patogeeniga, mille käsitlemine on rasken-
datud kõrgest (kolmas ohuklass) bioohutuse tasemest tulenevate töötingimuste 
tõttu. Seetõttu on CHIKV süvauuringuteks eriti vajalikud ohutud ja samas ka 
efektiivsed tööriistad.  
CHIKV infektsioon pärsib selgroogsest peremehest pärinevate rakkude 
metabolismi põhjustades tsütopaatilisi efekte ning lõpuks ka raku surma. See on 
vähemalt osaliselt põhjustatud nsP2 valgu toimest. NsP2 on multifunktsionaalne 
mittestruktuurne valk, mis lisaks oma funktsioonidele viiruse replikaasi 
kompleksis on ka raku transkriptsiooni ja translatsiooni mahasuruja. Peale selle 
on CHIKV ja teiste Vana Maailma alfaviiruste nsP2 vastutav tüüp-1 inter-
ferooni tootmise ja selle toime mahasurumise eest. Kuna tüüp-1 interferoonid 
on esmasteks viirusvastase kaitse vahendajateks võimaldab nende toime 
blokeerimine viirusel kiiremini paljuneda ja levida. NsP2 valgu tähtsusele 
nende protsesside mõjutamisel viitab ka asjaolu, et teatud mutatsioonid nsP2 
valgus võimaldavad persistentse infektsiooni kujunemist selgroogse peremehe 
rakkudes.  
Väitekirja kuuluvate tööde esimeseks eesmärgiks oli konstrueerida mitte-
tsütotoksilised CHIKV replikonid, mis võimaldavad neid sisaldavate imetaja 
rakkude paljunemist ning iseloomustada sellise fenotüübiga seonduvaid defekte 
nsP2 valgu funktsioonides ja/või viiruse RNA sünteesis. Töö käigus loodi 
vastavad BHK-21 rakkude põhised püsiliinid ja tehti kindlaks erinevad 
mutatsioonide kombinatsioonid nsP2 valgus, mis vähendasid CHIKV replikoni 
tsütotoksilisust. Iseloomustati ka mutatsioonid nsP1 ja nsP3 valkudes, mis 
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võimaldasid mittetsütotoksilise CHIKV replikoni püsimist inimese rakkudes. 
Läbiviidud analüüsid näitasid, et mutatsioonid nsP2 valgus mõjutavad selle 
ensümaatilisi aktiivsuseid ning vähenenud tsütotoksilisusega fenotüübid 
erinevad seda efekti põhjustavate molekulaarsete mehhanismide poolest. Ka 
leiti, et saadud püsivalt replitseeruvaid replikone sisaldavad ja nende vahen-
dusel markervalke tootvad rakuliinid kujutavad endast efektiivseid ja ohutuid 
tööriistu, mis võimaldavad CHIKV vastaste inhibiitorite otsimist ja nende toime 
analüüsimist. 
Siin kokku võetud tööde teiseks eesmärgiks oli CHIKV trans-replikaasi 
süsteemi väljatöötamine, iseloomustamine ja katsetamine. Selleks konstrueeri-
sime süsteemi, kus replikaasi valkude tootmine ja nende poolt läbiviidav RNA 
replikatsioon on teiseteisest lahutatud. Näitasime, et selline süsteem võimaldab 
uurida erinevate mutatsioonide või mittestruktuursetele valkudele lisatud tagide 
otseseid efekte replikaasi võimele läbi viia RNA sünteesi. Võrrelduna 
infektsioonilise viirusega omab CHIKV trans-replikaas sellistes analüüsides 
selgeid eeliseid, sest viiruse kontekstis põhjustavad paljud mutatsioonid 
geneetilist ebastabiilsust. 
Väitekirja kolmandaks eesmärgiks oli Semliki Forest viiruse (SFV) ja 
CHIKV trans-replikaaside kasutamine viirus-peremeesrakk vaheliste inter-
aktsioonide uurimiseks. SFV trans-replikaasi kasutades avastasime alfaviiruste 
replikaasi uue funktsiooni – võime kasutada rakulisi RNAsid sünteesimaks 
kaasasündinud immuunvastust aktiveerivaid kaheahelalisi RNA molekule. 
CHIKV trans-replikaasi kasutamine näitas, et selle viiruse metsik-tüüpi 
replikaas ei ole võimeline meie poolt kirjeldatud viisil immuunsüsteemi 
aktiveerima. Erinevate trans-replikaaside võrdlemine võimaldas kindlaks teha 
peamised faktorid, mis vastutavad raku RNAde põhiste kaheahelaliste 
molekulide sünteesi eest. 
Käesoleva uurimustöö käigus on loodud rida unikaalseid ja efektiivseid 
CHIKV molekulaarbioloogia uurimise tööriistu. Nende kasutamine on võimal-
danud paremini mõista nii CHIKV molekulaarbioloogiat kui ka alfaviirus- 
peremees vahelisi interaktsioone. Läbiviidud töö näitas, et kahe sarnase 
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